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 Hantavirus cardiopulmonary syndrome (HCPS) is characterized by 
fatigue, fever, and thrombocytopenia and results in pulmonary edema and shock.  
HCPS currently has a 36% mortality rate in the United States.  The small animal 
model for studying HCPS was the Syrian golden hamster (Mesocricetus auratus), 
which develops a similar disease when infected with Andes (ANDV) or Maporal 
hantavirus (MAPV).  We tested the use of anti-inflammatory cytokines, 
transforming growth factor-β1 (TGFβ1) or interleukin-10 (IL-10) as therapeutic 
agents for attenuating disease severity.  Gene expression in both lung and 
spleen suggested an innate immune response with elevation of STAT 1 and 
MxA.  The administration of TGFβ1appeared to suppress expression of several 
vasoactive cytokines, tumor necrosis factor (TNF), and interferon-γ (IFN-γ) in the 
lungs of infected animals and decreased lung congestion and pleural fluid 
volume; however, no significant attenuation of lesion severity was observed. 
Administration of IL-10 resulted in increased lesion score and no suppression of 
gene expression.  This suggested that the noncognate functions of TGFβ1 may 
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Humans have long been subjected to various infectious diseases, many of 
which have had lasting impacts on society.  A particularly significant example 
includes the bacterium Yersinia pestis that causes the plague.  Between 1346 
and 1350, this disease caused thousands of deaths, wiping out approximately 
one-fourth of the population of Europe.  Spread through bites from infected rat 
fleas, this disease manifests itself with swollen, discolored lymph nodes, leading 
to the name many are familiar with--the Black Death.  Currently, untreated plague 
has a mortality rate between 40-100% (Stenseth et al., 2008) and is still endemic 
in many rodent populations in the United States.  Another example of a 
historically significant infectious disease is smallpox, a once common childhood 
infection, caused by Variola virus.  This viral infection is highly contagious 
because it spreads by respiratory transmission.  Although vaccination efforts of 
smallpox have eradicated the virus, it is considered a potential bioterrorism 
weapon (Parrino & Graham, 2006).  
Many infectious diseases manifest as hemorrhagic fevers--diseases 
characterized by fever and bleeding diathesis.  Also consistent with these severe 
illnesses are fatigue, edema, and hypotension (Center for Disease Control, 




virulent and result in high mortality rates.  One of the earliest hemorrhagic fevers 
described is dengue hemorrhagic fever--an arborvirus transmitted by 
mosquitoes.  Between 1927 and 1928, this virus caused the deaths of over 1500 
people in Greece (Rosen, 1986).  Worldwide, this disease infects a staggering 
amount of humans (estimated to be 50 million per year), predominantly in Africa, 
Asia, and South America (Gurugama, Garg, Perera, Wijewickrama, & 
Seneviratne, 2010).  More recently, this virus has spread into North America for 
the first time, occurring in the Florida Keys (Center for Disease Control, 2010b). 
In addition to conditions that give hemorrhagic fevers their names, many 
also have a renal component.  One virus that causes such a disease is Seoul 
virus.  Seoul virus is a member of the genus Hantavirus, family Bunyaviridae. 
However, it should be noted that there are many other viruses that cause 
hemorrhagic fevers with renal complications.    
Although the hantavirus disease had occurred for centuries, hantaviruses 
were first noticed by Western scientists after they gained the interest of American 
military physicians during the Korean War in 1951.  In his 1953 paper, Joseph 
Smadel described the symptoms of a hemorrhagic fever in American troops and 
noted that the suspected reservoir was a rodent-associated arthropod.  However, 
it was later shown that it is transmitted directly by the rodents.  In 1976, Lee, Lee, 
and Johnson (1978) isolated the etiologic agent of Korean hemorrhagic fever 
from the striped field mouse (Apodemus agrarius coreae).  His group named the 
agent Hantaan virus after the Hantaan river region where the mice were found.  




this first identification, several other hantaviruses have been discovered including 
Puumala virus (host Clethrionomys glareolus) and Seoul virus (host Rattus 
rattus), both of which also cause hantavirus fever with renal syndrome (HFRS).    
Until the 1990s, hantaviruses had only been identified in Eurasian 
countries; those that were pathogenic resulted in diseases with a substantial 
renal component.  In 1993, an outbreak of an unknown illness occurred among 
otherwise healthy young people in the Four Corners region of the United States.  
Known as the Colorado Plateau, this area has varied types of vegetation that 
sustain numerous types of wildlife including many rodent species. 
Infected individuals were first presented at medical facilities in New 
Mexico with an abrupt onset of influenza-like symptoms including fever and 
headaches.  These symptoms then rapidly progressed into respiratory distress 
and non-cardiogenic shock (Center for Disease Control, 1993).  From December 
of 1992 through June 7, 1993, 24 victims were identified.  Fourteen of these 
patients became ill during May of 1993.  Of these initial 24 patients, 12 died 
resulting in a significant mortality rate of 50%.  By November of 1993, new cases 
brought the mortality rate to above 75% (Nichol, 1993). 
Polymerase chain reaction (PCR) analysis was conducted using tissue 
samples from victims to identify the agent responsible for the illnesses.  The 
sequences obtained were homologous to other known hantavirus species with a 
difference of approximately 30%.  Serology also suggested high cross-reactivity 




This led researchers to believe they were dealing with a previously undiscovered 
hantavirus most closely related with PHV and PUUV viruses.   
Since all known hantaviruses were hosted by rodents, investigators began 
trapping and testing rodents in the region.  The most commonly trapped rodent 
was the deer mouse (Peromyscus maniculatus).  Trapped deer mice were tested 
for the presence of antibody to conserved epitopes on various other 
hantaviruses.  Of all trapped deer mice, 30% had antibodies to hantavirus 
antigens.  PCR results demonstrated that the virus sequenced from the deer 
mice was identical to those from human cases (Childs et al., 1994), suggesting 
the etiologic agent was a hantavirus whose reservoir was the deer mouse.  This 
newly discovered hantavirus was eventually named Sin Nombre virus (SNV). 
Since the 1993 outbreak, more hantavirus cardiopulmonary syndrome 
(HCPS) cases have been attributed to other newly discovered hantaviruses in 
North and South America; the hosts for most of these have also been identified.  
In South America, several species of hantaviruses have been identified: Andes, 
Juquitiba, Araraquara, Laguna Negra-like, Castelo dos sonhos, and Anajatuba 
viruses.  Each of these has been associated with HCPS and has distinct rodent 
reservoirs (Oliveira et al., 2009).  It is likely that as more animals are tested, new 
species of hantaviruses will be found. 
While hantaviruses clearly cause dramatic health problems for infected 
humans, their reservoirs do not suffer ill effects.  Due to their ability to mount a 
non-sterilizing antibody response, it has been suggested that hantaviruses and 




an increased expression of the cytokine-transforming growth factor beta (TGF-
β1) and transcription factor fork head box P3 (FoxP3), which is suggestive of T 
regulatory cell involvement (Schountz et al., 2007).  The increase in this cytokine 
may be important in the deer mice’s lack of pathogenesis. 
The goal of this project was to further elucidate the role of TGF-β1 in the 
resistance of disease.  A better understanding of factors that aid in host 
resistance to disease may lead to therapeutics to treat infected patients. 
Aim 1 
 Aim 1 was to characterize the cytokine gene expression in Syrian golden 
hamsters infected with Maporal hantavirus (MAPV). 
 H1   The pulmonary inflammation in the lungs of hamsters infected with  
  Maporal virus is caused by inflammatory cytokines.   
Hamsters were infected with MAPV at the University of Texas Medical Branch in 
Galveston under biosafety level four safety conditions.  Messenger RNA was 
evaluated in lung, spleen, and kidney tissues of the infected animals. 
Aim 2 
Aim 2 was to characterize the effect of TGFβ1 or IL-10 treatment in Syrian 
golden hamsters infected with Maporal hantavirus.   
H2 The pulmonary inflammation observed in the lungs of hamsters  
infected with Maporal virus will be reduced with the administration 
of a TGF-β therapy.   
 
We infected hamsters with either MAPV or a saline control and then treated with 
active TGF-β, IL-10 or a saline control.  Pleural fluid was recovered at necropsy 






Aim 3 was to determine the viral load in lung, spleen, and kidney of 
hamsters infected with MAPV.   
H3   Viral replication occurs predominantly in the lung tissue of hamsters  
 infected with Maporal virus.  
RNA was extracted from lungs, spleens, and kidneys and reverse transcribed 
using primers specific to the nucleocapsid gene.  Viral cDNA was quantified 
using multiplex PCR with a probe to either the (+) or (-) strand using GAPDH as a 














 Deer mice are found throughout most of North America in a wide variety of 
environments and habitats.  Their main diet consists primarily of seeds and green 
vegetation.  Other hantaviruses causing HCPS exist in other rodent reservoirs 
including New York-1 virus (white footed mouse, Peromyscus leucopus) and 
Andes virus (long-tailed pygmy rice rat, Oligoryzomys longicaudatus).  Because 
an increasing number of rodents is now associated with emerging zoonotic 
diseases, scientists have a greater appreciation of the importance of these 
associations.  Where rodents are found, there is also the possibility of an 
associated hantavirus.  Many of the identified viruses may have no or little 
pathogenicity in humans.  There have been species identified that do not cause 
human disease, e.g., Prospect Hill, Tula, and Thottapalayam viruses.  The 
degree of pathogenicity may be due to immune evasion strategies that have yet 
to be fully elucidated.  Studies suggest that the difference in pathogenicity may 
be due to the innate interferon response.  When Vero E6 cells (which are 
defective in the type I interferon pathway) were infected with pathogenic viruses 
(SNV, HTNV, Seoul) and non pathogenic viruses (PH, Tula, Thottapalayam), the 




infect A549 lung cells, the non pathogenic strains induced a strong interferon 
response as measured by MxA and IFN-β.  This response was not observed 
using pathogenic hantaviruses until later time points (Shim et al., 2011).  When 
Tula and HTNV were used to infect human endothelial cells, it was observed that 
the HTNV had a faster replication rate.  This correlated to a decreased 
expression of MxA as compared to Tula.  It was also observed that HTNV had 
decreased expression of major histocompatibility complex I (MHC I) compared to 
the non pathogenic virus (Kraus et al., 2004).  Appendix A lists known 
hantaviruses and their reservoirs. 
 It has been suggested that hantavirus developed co-evolutionary 
relationships with their rodent hosts (Yates et al., 2002).  Phylogenetic analyses 
revealed that the more similar the rodent hosts, the more similar the infecting 
hantaviruses.  HCPS is a New World disease found primarily in Sigmodontinae 
rodents; whereas, a less severe form of hantavirus disease with a renal 
component (HFRS) is seen in Eurasian continents.  It has been speculated that 
the New World hantaviruses were carried to the Americas on ships and mutated 
as they spread across North and South America and crossed species (Morzunov 
et al. 1998; Plyusnin, 2002).  This suggestion of genetic drift is supported by 
studies that demonstrated many hantavirus species differ by only a few point 
mutations, yet have distinct rodent hosts (Plyusnin, 2002).  Several phylogenic 
studies have evaluated the relatedness of rodent hosts using trees prepared from 
rodent genetic sequences and sequences encoding the glycoprotein epitopes of 




evidence for host switching approximately two to four million years ago 
(Morzunov et al., 1998; Nemirov, Henttonen, Vaheri, & Plysnin, 2002; Vapalahti 
et al., 1999).  Hence, it is still likely to see the evolution of new hantaviruses over 
time.  While such studies support a hypothesis for co-evolution of virus host 
relationships, it should be noted that other host virus relationships have been 
observed, namely in arenaviruses with their rodent reservoirs.  A capture study of 
rodents in central Venezuela suggested specific host relationships also existed 
between these viruses and a rodent host.  Captured Sigmodon alstoni (cotton 
rats) were infected with Pirital arenavirus while Zygodontomys brevicauda (cane 
mice) were infected with Guanarito arenavirus, even though these two rodents 
occupied the same habitat (Bowen, Peters, & Nichol, 1997; Fulhorst et al., 1999). 
 SNV has likely been circulating in deer mouse populations for many years.  
After the 1993 outbreak, researchers evaluated tissue samples from deer mice 
collected from 1989-1993 at the Sevilleta Long Term Ecological Research Center 
(LTER) in New Mexico.  Samples collected in 1989 showed that only small 
percentages of deer mice were infected with SNV.  By 1991, the incidence of the 
virus in deer mice was distributed over 100,000 hectares, indicating it could 
spread easily between deer mice (Yates et al., 2002).  In preserved human 
tissues kept from the 1970s, several individuals who died from respiratory 
disease were found to have been infected with SNV (Zaki et al., 1996), indicating 
the virus was present prior to the 1993 outbreak. 
 It has been postulated that the outbreak in 1993 was due to the 1992 El 




area increased dramatically according to data collected at the LTER (Yates et al., 
2002).  Precipitation during this time increased more so than in previous years, 
providing increased vegetation and habitats for deer mice. This increase in the 
deer mouse population spilled over into human habitats such as sheds and 
woodpiles, thus providing an opportunity for human exposure. 
 After identification of the virus as a potential hantavirus (during the 1993 
outbreak), scientists from the Centers of Disease Control and Prevention (CDC) 
in collaboration with researchers from Colorado State University and the 
University of New Mexico trapped over 1,000 rodents from various sites 
surrounding the Four Corners region.  The majority of rodents trapped were from 
either the Peromyscus (mouse) or Tamias (chipmunk) genera.  Of all trapped 
animals, 47.9% were Peromyscus maniculatus.  Serological assays were used to 
evaluate if rodents had antibodies to known hantaviruses that caused HFRS.  
Deer mice had the highest rates of reactivity to PHV and SEOV.  These animals 
also had virus in their tissues as evaluated using polymerase chain reaction 
(PCR; Childs et al., 1994). 
 Lung tissue was obtained from two infected deer mice for viral RNA 
sequencing.  Primers were designed using aligned hantavirus sequences from 
Puumala (PUUV) and Prospect Hill viruses for viral gene amplification.  The 
amplified PCR products were sequenced and compared to known hantaviruses 
using phylogenetic tree analysis, resulting in a novel hantavirus.  The new virus 




PUUV.  Due to concerns from the local tourist industry, the name of the virus was 
later changed to Sin Nombre virus (Hjelle et al., 1994).  
 In 2000, a deer mouse colony was founded at the University of New 
Mexico using wild caught deer mice.  When these mice were infected with SNV, 
researchers did not note a difference in the lung tissue between infected and 
uninfected controls (Botten et al., 2000).  In this experiment, animal tissues were 
perfused with formalin fixed upon euthanization and paraffin embedded.  They 
were evaluated using hemotoxylin and eosin staining; the results are the most 
reliable to date (Botten et al., 2003).  A separate study prepared SNV specific 
antigen and used this to generate specific anti-SNV antibodies.  These 
antibodies were then used to evaluate presence of viral antigen in experimentally 
infected deer mice tissues.  Positive staining for virus was observed in cardiac 
and pulmonary (lung) tissues; however, no apparent pathology was noted in 
these tissues (Green et al., 1998).    
 In experimentally infected deer mice, viral RNA was predominantly in the 
lung, heart, and brown fat at days 14-35 post-infection (Botten et al., 2003).  
Levels peaked between day 60 and 120 days post-infection (dpi) when viral 
antigen was evaluated using immunohistochemistry (IHC) and then decreased; 
however, the virus was still readily detectable by PCR.  Antibodies to the viral 
nucleocapsid were detected beginning at day 14 and continuing to the day 28 
endpoint.  These data suggest the virus may have developed persistent infection 




 The virus replicated in lung endothelial cells; however, little if any 
cytopathic effect was observed in these cells.  Peak values of positive strand 
vRNA were observed between days 21 and 60 post-infection in the heart, lung, 
brown fat, and kidney.  Values began to decrease after day 60; only the lung, 
heart, and brown adipose tissue (BAT) displayed appreciable levels of vRNA with 
the highest levels present in the lungs (Botten et al., 2003).  Positive strand 
vRNA decreased dramatically after 60 days post-infection, indicating that the 
virus was not actively replicating and producing viral proteins.  As the levels of 
viral and message RNA decreased, there was an increase in neutralizing 
antibody titers that peaked between days 120 and 180 post-infection (Botten et 
al., 2003).   
 One study evaluated the potential of SNV to replicate in T cells.  Cells 
from infected deer mice were cultured and evaluated for the presence of vRNA.  
After 25 days of culture, vRNA was never detected in the T cells, suggesting that 
these cells were not capable of hosting replicating virus nor were they a likely 
location of persistent viral infection (Schountz et al., 2007).  
 Assessing the deer mouse immune response to SNV infection has been a 
challenging task, predominantly due to a lack of reagents.  Many mRNA 
sequences and proteins of commonly used laboratory animals (mice, rats, etc.) 
do not share significant homology with the deer mouse.  Progress has been 
made as several deer mouse immune genes have been sequenced; however, 
the corresponding proteins are not yet available (Oko et al., 2006).  Progress is 




sequences can be used to detect immune gene regulation using techniques such 
as in-situ hybridization and PCR.  This will allow a better evaluation of the 
immune response to SNV in the deer mouse. 
 In studies from persistently infected animals, there appeared to be a 
development of an anti-inflammatory response (Mori et al., Schountz et al., 
2007).  One study evaluated the gene expression of available deer mouse 
genes.  T cell proliferation from experimentally infected deer mice was assessed 
by culturing spleen cells from infected deer mice and challenged with SNV 
nucleocapsid antigen.  T cells from infected deer mice had weaker proliferation 
than those from control animals.  Additionally, the T cell cytokine profiling 
indicated increased expression of TGFβ1 in persistently infected deer mice, 
suggestive of a T regulatory cell response that may be mediating an 
inflammatory reaction to the virus.  Interestingly, interleukin-10 (IL-10) expression 
was decreased in these animals along with Interferon gamma (IFN-γ).  There 
was also a noticeable lack of tumor necrosis factor up regulation, which has been 
implicated in human pathology (Mori et al., Schountz et al., 2007).  These 
findings are supported by a similar study (Easterbrook, Zink, & Klein, 2007) using 
Seoul virus (an HFRS-causing hantavirus) in the reservoirs of Norway rats 
(Rattus norvegicus).  In addition to observing an increase in TGFβ1 in the lungs 
of infected animals when T regulatory cells were depleted, the expression of 
TGFβ1 significantly decreased.  Levels of TNF were also notably higher in 
infected animals compared to infected animals with inactivated T regulatory cells 




secrete TGFβ1, which may then decrease expression of TNF (Wei et al., 2008).  
Thus, it is not surprising that suppressing T regulatory cells may also attenuate 
TNF levels.  
Pathology of Human Hantavirus  
Cardiopulmonary Disease 
 
 Sin Nombre virus infects humans principally by the respiratory route.  The 
virus, excreted from the deer mice, is aerosolized and inadvertently inhaled.  This 
is typically done during the sweeping and cleaning of areas mice inhabit, e.g., 
outdoor sheds and woodpiles.  Upon entering the respiratory tract of an 
individual, the virus binds to endothelial cells.  In a study (Yanagihara & 
Silverman, 1990) using Seoul, Hantaan, Puumala, and the non pathogenic 
Prospect Hill and Leaky hantaviruses, human vascular endothelial cells and 
human umbilical vein endothelial cells were infected with virus.  Although these 
viruses cause HFRS, their transmission to humans is also through the respiratory 
route.  Cells were observed at 3 days post-infection and 10 days post- infection.  
Approximately 20% of endothelial cells and 100% of the HUVECs had 
cytoplasmic staining for virus.  However, no conspicuous cytopathic effects were 
observed in the infected cells study (Yanagihara & Silverman, 1990).  This 
suggests that HFRS-causing viruses can bind to a receptor on these cells and 
enter into the cytoplasm, making them a potential target for infection. 
 Pathogenic and nonpathogenic hantaviruses enter cells by using a Beta-
integrin receptor.  A study by Gavrilovskaya, Shepley, Shaw, Ginsberg, and 
Mackow (1998) showed that when Vero E6 cells and Chinese hamster ovary 




approximately 70% inhibition of viral infection with New York hantavirus (a HPCS 
virus), indicating this virus used a cellular entry.  Nonpathogenic Prospect Hill, 
Tula, and Thottalapom viruses were inhibited by fibronectin, indicating β1 
integrins were required for their entry (Gavrilovskaya et al., 1998).  In addition, 
when HUVEC cells were pretreated with an anti-β3 antibody, infection with 
pathogenic hantavirus was blocked.  This was not observed using non-
pathogenic virus, indicating that the cellular receptor used to gain viral entry may 
be significant to pathogenicity. 
 A study using Andes hantavirus demonstrated that infection of hamster 
trachea epithelial cells (TEC) can occur at both the apical and basolateral 
membranes (Rowe & Pekosz, 2006).  However, the cells infected at the apical 
membrane supported viral replication more than the other (100 fold difference in 
viral RNA copy number).  When the cells were double stained with markers for 
ciliated and non-ciliated cells, Andes infected the non-ciliated cells 
predominantly.  Furthermore, the non-ciliated cells expressed β3 integrin more 
than ciliated cells (Rowe & Pekosz, 2006).  Once virus has been released inside 
the host cell, it uses an RNA dependent RNA polymerase (RdRp) for viral 
replication and transcription of viral proteins.  Hantaviruses are negative sense 
RNA viruses and synthesize a plus strand that functions as messenger RNA for 
translation or as a template for new viral RNA for viral replication.  SNV contains 
an L segment (encodes the RdRp), M segment (encodes viral glycoproteins Gc 




 After transcription and translation of viral polypeptides, vRNA is 
synthesized and packaged into the nucleocapsid.  The glycoproteins and 
nucleocapsid are co-localized in the Golgi complex, although the location of the 
viral packaging in the host cell is unknown (Li et al., 2010). 
 While it is accepted that hantavirus can infect and replicate within 
endothelial cells, little is known of how the virus spreads to other cells in the 
body.  There are currently no published reports explaining viral shedding from 
endothelial cells.  As it is an enveloped virus, it can be hypothesized that the 
virus buds out of infected endothelial cells. 
 Hantaviruses have been shown to infect monocytes/macrophages where 
the virus can also replicate, demonstrated by in vitro assays using HFRS that 
causes hantaviruses (Nagai et al., 1985; Temonen et al., 1993).  However, this 
has yet to be shown in models using HCPS hantaviruses. 
 Other cells that may be subject to infection are dendritic cells.  Human 
dendritic cells have been successfully infected with Hantaan virus in vitro 
(Raftery, Kraus, Ulrich, Kruger, & Schonrich, 2002).  Dendritic cells were 
incubated with HTNV; after four days, nucleocapsid antigen could be identified in 
cells, which also correlated with a peak in viral titer in cell supernatant.  Follicular 
dendritic cells in autopsy sections have also been observed to contain SNV 
antigen by immunohistochemistry, suggesting they too may be infected (Zaki et 
al., 1995).  However, it cannot be discounted that these cells may simply be 





 People infected with SNV typically have flu-like symptoms.  During the 
1993 outbreak, individuals infected with SNV proceeded to die an average of four 
days after the onset of symptoms (Zaki et al., 1995).  The average incubation of 
exposure to symptoms is 9 to 33 days (Young et al., 2000). 
 After the incubation period, the disease follows a pattern that includes five 
distinct phases: Phase 1--fatigue, fever, vomiting; Phase 2--thrombocytopenia; 
and Phase 3--pulmonary edema.  The fourth and fifth phases are signaled by 
dieresis and a slow recovery, respectively (Jonsson, Hooper, & Mertz, 2008; 
Maes, Clement, Gavrilovskaya, & Van Ransdt, 2004). 
 Treatment of HCPS is limited, in part, due to not being recognized until 
late in its progression.  Antiviral therapies with ribavirin have been successful 
with HFRS (Chapman et al., 1999; Huggins et al., 1991).  A recent report using 
the Andes hamster model demonstrates that ribavirin (an anti-viral medication 
commonly used to treat hepatitis) can prevent lethal HCPS disease when 
administered either intravenously or orally and decreases disease severity 
(Safronetz, Haddock, Feldmann, Ebihara, & Feldmann, 2011).  Currently, the 
most successful treatment regimen used in humans is extracorporeal membrane 
oxygenation or ECMO (Dietl et al., 2008).  This is also known as heart lung 
bypass--the blood is oxygenated in a machine outside the body and then 
returned.  According to the Center for Disease Control (2010a), reports of 
mortality were 29% in 2010; overall, they were 35% from 1993-2009 (MacNeil, 





The Innate Immune Response 
 The human immune response includes both innate and adaptive 
mechanisms.  Most viruses are typically engaged by the host innate responses, 
while an adaptive response develops and is more effective later in the course of 
disease.  Innate molecules include pattern recognition receptors (PRR), 
cytokines, complement, phagocytic cells, and interferons. 
 In many human pathogens, viral RNA can cause an interferon response 
by binding to a PAMP such as TLR3 or RIG-I.  These proteins activate immune 
gene transcription factors, namely, IFN regulatory factor 3 (IRF-3) and IFN 
regulatory factor 7 (IRF-7), both which play a role in the transcription of 
interferons α and β.  These interferons then activate interferon stimulated genes 
(ISG) such as MxA and ISG56.  SNV appears to be able to also turn on ISGs 
without using IRF-3 or IRF-7 (Prescott, Hall, Bondu-Hawkins, Ye, & Hjelle, 2007).  
When IRF-3 and IRF-7 were silenced in hepatoma cell line Huh3, there was still 
increased expression of ISG when exposed to irradiated SNV as compared to 
controls (Prescott et al., 2007).  It is plausible that the Gc cytoplasmic tail could 
be functioning by interacting with transcription factor CREB for regulation of 
interferon expression.   
 The interactions of PRRs and interferon (IFN) regulation have been given 
particular attention in their response to hantavirus infection.  In a study by 
Prescott, Ye, Sen, and Hjelle (2005), endothelial cells were infected with SNV 
and gene expression evaluated by microarray and quantitative PCR.  These 




Both groups were studied at early time points (<24 hours) and later time points 
(three days).  At 24 hours, there was no measurable difference in interferon 
stimulated genes (ISG) including MxA and ISG56 (both were elevated).  This 
suggests that initially a particle of SNV may be used as a pathogen associated 
molecular pattern (PAMP) instead of double stranded RNA activating Toll-like 
receptors to trigger enhanced ISG expression.  At day 3 post-infection, the cells 
treated with active (replicating) virus continued to induce ISG; whereas, the other 
group had reduced expression (Prescott et al., 2005).    
 However, a study by Alff et al. in 2006 showed that pathogenic hantavirus 
NY-1, an HCPS causing virus and HTNV, decreased interferon signaling at day 1 
post-infection as measured by interferon response genes (ISG) MxA and ISG56.  
However, non-pathogenic PHV, which was used as a control, did not have this 
reduction in gene expression.  By day 3 post-infection, all viruses had reduced 
MxA expression; however, it was still notably elevated in PHV as compared to 
NY-1.  Additionally, NY-1 and HTNV had increased S segment gene expression, 
indicating they could replicate inside the endothelial cells.  PHV had very little S 
segment gene expression.   
 This study also demonstrated that cells treated with the Gc cytoplasmic 
protein of pathogenic hantavirus reduced RIG-I (retinoic acid inducible gene) 
function.  Cells were transfected with a RIG-I and interferon stimulated response 
element (IRSE) driven luciferase gene; decreased activity was observed when 
cells were also co-transfected with the  Gc portion of NY-1 as compared to the N 




that the Gc portion of pathogenic hantavirus may function as an inhibitory 
molecule of RIG-I and limit the downstream innate type I IFN response (Alff et al., 
2006).   
 A subsequent study (Shim et al., 2011) used A549 and Vero E6 cells to 
study the differences of innate immune responses to pathogenic and non 
pathogenic hantaviruses.  Both sets of viruses could replicate easily in Vero E6 
cells; however, in A549 cells only, the pathogenic viruses had replication 
equivalent to rates seen in Vero E6 cells.  This also correlated with a delayed 
increase in MxA and IFN-β (Shim et al., 2011). 
 Collectively, results of such studies indicate that pathogenic hantaviruses 
are delaying or subverting the type I interferon response to allow for increased 
viral replication and dissemination. 
Cell Mediated Host Response 
 In addition to innate responses, an adaptive immune response also 
appeared relevant during hantavirus infection.  A hallmark study by Zaki et al. in 
1995 showed the pulmonary infiltrate of infected individuals contained both CD4+ 
and CD8+ T cells along with macrophages.  The most common T cell subtype 
was the CD8+ phenotype.  This cell type binds to cells displaying antigen in a 
MHC I.  In a study infecting endothelial cells with HTNV (Kraus et al., 2004), 
there was a delayed increase in MHC I production (peak levels day 4-5- post-
infection) as to cells infected with a non pathogenic Tula virus, which had a peak 




 As T cells and macrophages are well known producers of inflammatory 
cytokines, researchers have begun to evaluate the presence of cytokines in 
lungs and spleens of infected individuals.  Cytokine presence has been 
evaluated by immune staining in both the lung and spleen of infected individuals.  
T cell cytokines IFNγ, IL-2, IL-4, lymphotoxin (LT), and TNF were increased in 
lung and spleen tissues, as well as monocyte derived IL-1α, IL-1β, and IL-6 (Mori 
et al., 1998).  The presence of cytokine producing T cells is suggestive of an 
immune response to HPS infection that may mediate capillary leak, causing the 
pulmonary edema seen in these patients. 
 In blood samples from infected individuals, CD8+ T cells have been 
isolated that immunoprecipitate with specific regions of the SNV nucleocapsid 
protein.  When amino acid substitutions were made in the nucleocapsid region, 
they were no longer recognized.  Cell death was averted when anti-MHC-I 
antibody was added to the experiment.  From these data, it could be 
hypothesized that the alveolar monocytic cells were presenting SNV 
nucleocapsid antigen in the MHC-I complex and activating CD8+ T cells (Ennis et 
al., 1997; Zaki et al., 1995).  Memory CD8+ T cells have been isolated from 
patients who fully recovered from Hantaan infections.  One sample recognized 
the Gc portion and two others recognized a region of the nucleocapsid.  When 
these cells were exposed to SNV peptides, they only recognized the C terminal 
region of the nucleocapsid, which tends to be conserved across all hantaviruses 
(Van Epps, Schmaljohn, & Ennis, 1999).  A subsequent study (of 78 




post infection with Andes hantavirus continued to have CD8+ T cells that were 
specific for the C terminal region of the nucleocapsid (Manigold et al., 2010).  
Two patients infected with SNV also had CD8+ T cell responses measured by 
SNV nucleocapsid antigen T cell recall assays (Ennis et al., 1997).  Collectively, 
these studies provide evidence that upon infection with SNV, patients develop a 
CD8+ T cell response.  Hence, the virus must be processed using the MHC-I 
pathway.  It is well known that SNV has tropism for endothelial cells; however, no 
cytopathic effects were observed.  Some studies have suggested that the HPS 
hantavirus can also infect alveolar macrophages and dendritic cells.  It could 
possibly be these macrophages display the nucleocapsid antigen for CD8+ T cell 
recognition (Nagai et al., 1985, Raftery et al., 2002; Temonen et al., 1993; Zaki et 
al., 1995). 
 Although less has been studied regarding CD4+ T cells, such a response 
must occur because IgG antibodies have been detected during acute and 
convalescent patients.  In acute patients there is a high titer of IgM and IgG 
antibodies, indicating a CD4+ T cell and B cell interaction.  IgA titers are also 
observed, which most likely come from the epithelial mucosa where primary 
infection occurs (Bostik et al., 2000). 
 It must also be considered that HCPS may not be a T cell mediated 
disease, at least in the traditional sense.  A study by Hammerbeck and Hooper 
(2011) evaluated T cell responses in hamsters infected with ANDV.  Their study 
used cyclophosphamide to inactivate T cells and anti-CD8 antibody to specifically 




infection with ANDV did not alter disease pathology (Hammerbeck & Hooper, 
2011). 
Animal Model of Disease 
 Until recently, study of hantavirus pathogenesis has been slowed by the 
lack of an animal model.  The usual laboratory mice and rat strains do not 
develop a clinical response to viral infection (Wahl-Jensen et al., 2007).  In 2002, 
it was discovered that Syrian golden hamsters could become infected with Andes 
virus (a South American HCPS virus) and suffer a clinical course similar to 
humans with HCPS.  Hamsters infected with Andes virus were asymptomatic for 
the first 10 days.  At day 11, post-infection hamsters became moribund, 
developing respiratory distress and dying within 24 hours of onset of symptoms.  
Similar to human disease, the animals had pleural edema and an increase in 
lymphocyte infiltration in the lungs.  Spleens were enlarged and had large, 
possibly apoptotic cells in the red pulp.  Viral antigen was observed in vital 
organs--liver, kidney, lung, spleen, and heart.  It should be noted that no 
infectious virus was found in brain tissue.  Although the virus is highly lethal in 
hamsters, those that survived after 12 days developed neutralizing antibodies to 
the virus.  When subsequently challenged again, they did not develop the 
disease (Hooper, Larsen, Custer, & Schmaljohn, 2001). 
 Hamsters infected with MAPV became symptomatic beginning day 8 post-
infection (lethargic, loss of appetite).  Beginning of day 9 post infection, animals 
become moribund.  As with the Andes model, surviving animals became clinically 




animals had reddened lungs that had also developed fibrin deposits, congestion, 
and edema. As in humans and Andes models, there were also macrophages and 
lymphocytes in increased numbers compared to control animals.  Viral antigen 
was commonly found in the lungs, lymph nodes, spleen, and kidney (Milazzo, 
Eyzaguirre, Molina, & Fulhorst, 2002). 
Transforming Growth Factor Beta-1 
 Transforming Growth Factor-Beta-1 (TGFβ1) has been implicated as a 
potential factor in the persistent infections of hantavirus in both the SNV and 
Seoul reservoirs (Easterbrook et al., 2007; Schountz et al., 2007).  It may be that 
TGFβ1 drives the development of T regulatory cells that suppress inflammation 
while an adaptive immune response builds.  Although the adaptive response is 
not sterilizing, it most likely serves to inhibit any pathology. 
 TGFβ1 is a multifunctional cytokine that consists of three different 
isoforms (TGFβ-1, 2, 3) found on three separate genes.  All exhibit similar 
biological effects such as cell growth, embryogenesis, tissue remodeling, and 
repair. They are not secreted by one cell type or organ; rather, they are found in 
all systems in the body.  All forms have a molecular weight of 25kDa and consist 
of two identical monomers, each 112 amino acids in length and held together by 
disulfide bonds (Koppa, 1994).  
 Although their functions are similar, the magnitude of their action depends 
on the isoform.  TGFβ1 is of particular interest as it is essential in normal (tissue) 
repair processes.  TGFβ1 induces the production of extracellular matrix proteins 




the accumulating matrix, resulting in buildup of fibrotic scar tissue (Border & 
Noble, 1993).  This sclerotic process is similar to scar formation when cut skin is 
healed.  The scar is a meshwork of extracellular matrix proteins that close up the 
wound. 
 TGFβ1 is initially secreted from cells in an inactive form and is non-
covalently bound to a latency associated peptide (LAP) at the N-terminus of TGF 
(Crawford et al., 1998).  The LAP-TGFβ1 complex is non-covalently bound to 
another molecule--Latent TGFβ1 Binding Protein (LTBP.)  It has been suggested 
that the LTBP may increase TGFβ1’s affinity for cellular receptors.  This LAP- 
TGFβ1-LTBP complex may enhance the stability of TGFβ1 in the extracellular 
matrix ready for activation (Crawford et al., 1998; Munger et al., 1997).  
 The LAP portion of the pro TGFβ1 is cleaved from the TGFβ1-LAP 
complex to activate TGFβ1.  TGFβ1 has been found to signal cells via 
serine/threonine kinases (Souchelnitskiy, Chambax, & Feige, 1995).  Active 
TGFβ1 binds to a kinase receptor called TGF Receptor-II (TGR-II) that recruits 
and forms a complex with TGF Receptor-I (TGR-I).  TGR-I has a phosphate on 
the intracellular domain and TGFβ1 binding is followed by a TGF receptor 
phosphorylation reaction and propagation of a signal using the SMAD pathway 
(Bottinger, Letterio, & Robers, 1997). 
 TGF β1 is a pleiotropic cytokine.  In addition to growth and healing, it is 
also capable of anti-inflammatory functions.  Macrophages that phagocytose 
apoptotic cells as a function of the immune pathway secrete increased levels of 




function to down regulate the inflammatory cytokine tumor necrosis factor (TNF) 
produced by macrophages (Fadok et al., 1998).  TGFβ1 is also released from T 
cells upon apoptosis; this TGFβ1 can further suppress inflammatory cytokine 
production from macrophages (Chen, Frank, Jin, & Wahl, 2001).   
 The expression of TGFβ1 can be induced by cross linking of the CTLA-4 
in CD4+ T cells, which then inhibits T cell proliferation (Chen, Jin, & Wahl, 1998).  
Interestingly, recent studies have demonstrated a role of TGFβ1 in the induction 
and proliferation of peripheral T regulatory cells.  When CD4+CD25+T cells are 
stimulated with TGFβ1 and IL-2 they become inducible T regulatory cells (iTregs) 
that are positive for Forkhead Box p3 transcription factor (Zheng, 2008).  When 
iTregs cells are transplanted into a murine hepatitis model, pathology is 
decreased.  This effect is blocked when anti- TGFβ1 antibodies are added(Wei et 
al., 2008).  This suggests that the iTreg response controlling liver inflammation is 
mediated by TGFβ1.  Another study also evaluated iTregs ability to control 
endothelial cell activation by measuring the level of E-selectin present on these 
cells.  Cells were induced to become iTregs by TGFβ1 and the supernatant used 
to measure the migration ability of Th1 cells through heart muscle endothelial 
cells.  The use of the iTreg supernatant significantly limited the ability of Th1 
migration.  It was also shown that levels of E-selection were decreased after 
exposure to the iTreg supernatant (Maganto-Garcia et al., 2011).  This suggests 
that TGFβ1 induced Tregs can decrease tissue inflammation by restricting the 





Evidence for Cytokine Therapy 
 Although cytokines may appear to be attractive modalities for a variety of 
diseases, very few have been utilized in viral infections.  For the most part, 
strategies to fight viruses are immunization (when available) and anti-viral 
medications, such as ribavirin, that block viral replication. 
 One of the first cytokines that was evaluated for efficacy in viral infection 
was a mixture of Interferon-α (IFNα) and Interferon-β (IFNβ).  During initial 
experiments, it was discovered these molecules have anti-tumor activity and 
focus shifted toward using them for this purpose.  However, IFN-β in particular 
has found use for treatment of multiple sclerosis (trade names Rebif, Avonex), 
which is thought to be triggered by a still unknown virus.  Clinical studies have 
shown that IFN-β treatments decrease relapse rates of Multiple Sclerosis by 
approximately 30% and new lesion activity by about 65% (Rudick & Goelz, 
2011).  IFN-α is one of the most popular treatments for hepatitis C, a chronic liver 
infection caused by the hepatitis C virus.  The success of IFN-α treatment 
depends on the patient genotype but complete remission has been observed.  
Due to the ability of the virus to mutate rapidly, the use of a cytokine therapy has 


















 For the first set of experiments evaluating gene expression, 12 four-week- 
old out bred female Syrian golden hamsters (Harlan Sprague Dawley) were used 
for experiments and divided into three groups: (a) uninfected controls, (b) MAPV 
infected and euthanized at day 8 post-infection, and (c) MAPV infected and 
euthanized at day 10 post-infection.   
 Animals were infected by intramuscular injection into the right hind leg with 
a 0.2 mL suspension containing 3.1 log10 median cell culture infectious doses in 
PBS of the MAPV strain 97021050 (Milazzo et al., 2002).  Animals were housed 
under BSL-4 safety conditions at the University of Texas Galveston medical 
branch (UTMB) and treated in accordance with UTMB animal handling guidelines 
and approved protocol.  
PCR for Gene Expression 
 Tissues were homogenized in Trizol reagent (Invitrogen) by collaborators 
in Texas and shipped to the University of Northern Colorado in 1 mL aliquots.  
Two hundred microliters of chloroform were added to each sample and incubated 




15 minutes at 4° C.  The aqueous upper layer was removed and transferred to a 
fresh tube with an equal volume of 70% ethanol and mixed.  RNA was purified 
over RNAeasy columns according to kit instructions (Qiagen).  Samples were 
bound to spin columns for 15 seconds at 8,000 x g at room temperature and then 
washed using kit buffers.  RNA was then eluted from columns using sterile 
Millipore water by spinning for one minute at 8,000 x g.  All RNA samples were 
stored at -80° C. 
 Reverse transcription PCR (RT-PCR) was performed using random 
hexamers and a qScript kit (Bio-Rad).  Three microliters of RNA was added to 4 
uL of reaction buffer, 1 uL reverse transcriptase, and 10 uL of RNAse free water 
(all provided by the kit manufacturer.)  Samples were then reverse transcribed 
into cDNA using a Bio-Rad thermocycler under the following conditions:  25°C for 
5 minutes, 42°C for 30 minutes, and 85°C for 5 minutes.  Samples were kept 
frozen at -20°C until used.   
 The cDNA generated was used for quantitative real time PCR using 
primers established by Zivcec, Safronetz, Haddock, Feldmann, and Ebihara 
(2011; see Appendix C).  The protocol for the quantitative PCR assay was 
adapted from a previously established protocol (Oko et al., 2006).  Thirty-nine 
microliters of the cDNA were mixed with 487.5 uL of Millipore water and 487.5 
SYBR Green reaction mix.  Aliquots of 45 uL were added to real time plates and 
5uL of primers were added.  Experiments were performed using the iQ SYBR 
Green kit for 40 cycles (45 seconds at 94°C, 50 seconds at 54°C, and 60 




values were calculated by averaging the relative fluorescence unit from cycles 
10-14, +3 standard deviations.  Values were considered positive when they 
reached this value and were continuously 20% over previous values.  Fold 
expression was calculated using the delta delta Ct method. 
Aim 2 
Animals 
 Forty-two 4-week-old out bred Syrian golden hamsters (female) were used 
for the experiments.  Animals were divided into the following groups: (a) MAPV 
infected and treated with TGFβ1, (b) MAPV infected and treated with IL-10, (c) 
MAPV infected and treated with 1x PBS, (d) MAPV infected only, (e) TGFβ1 
treatment only, (f) IL-10 treatment only, and (g) 1x PBS only.  One day prior to 
infection, hamsters were anesthetized and surgically implanted subcutaneously 
between the scapulae with ALZET osmotic pumps (Model 2001).  Incisions were 
closed using 3M Precise disposable skin staplers.  Pumps contained either 200 
ng active human rTGFβ1 or interleukin-10 (R&D Systems) in 200 µL of PBS or 
PBS only.  These pumps are designed to release 1 uL/hour of solution so that 
animals received a continual dose of 1 ng/hour of the treatment cytokine.   
 Animals were infected by intramuscular injection into the right hind leg with 
a 0.2 mL suspension containing 3.1 log10 median cell culture infectious doses in 
PBS of the MAPV strain 97021050 (Milazzo et al., 2002).  Animals were housed 
under BSL-4 safety conditions at the University of Texas Galveston medical 
branch and treated in accordance with UTMB animal handling guidelines and 




TGFβ1 Dosing Study 
 To evaluate appropriate dosage of TGFβ1 into Syrian golden hamsters, 
animals were assigned to one of five groups: A, B, C, D, or E.  Group A served 
as a control group and received infusions of saline.  Groups B, C, D, and E 
received infusions of recombinant TGFβ1 (R&D Systems).  Groups were dosed 
at concentrations of 20 ng, 200 ng, 2,000 ng, and 20,000 per mL, respectively.  
Each group was made up of four hamsters for a total of 20 animals.   
 TGFβ1 was administered using ALZET osmotic pumps for seven days.  
Hamsters were anesthetized with 3% isoflourane and fur plucked from incision 
site.  Surgical sites were cleaned using betadine wipes and 70% ethanol.  
Incisions were made in the subscapsular area using surgical scissors and pumps 
inserted with hemostats.  Incisions were then closed using 3M Precise surgical 
staples.  Polysporin was administered to the wound to prevent infection.  Animals 
were then warmed and observed during recovery.  Hamsters were observed 
daily for biological effects by appearance, food and water consumption, behavior, 
and weight.  Observations were recorded and scored in a table (see Appendix 
C.)  After seven days, animals were euthanized using respiratory hyper 
anesthesia with isoflourane and compromise of the pleural sac.  Organs were 
removed for histological evaluation of pathology compared to the control group. 
Pathology 
 Pleural fluid was collected from each animal upon death by aspiration with 




 Tissues were fixed in 10% neutral buffered formalin, processed routinely, 
and embedded in paraffin.  Five m thick sections were prepared, stained with 
hematoxylin-eosin, and evaluated by light microscopy.  Histopathologic lesions 
were scored based on the severity of lesions utilizing the following grading 
scheme.  Histologic sections of lung were scored on a 0-9 (0--no discernible 
lesions, and 9--most severely affected) scale based on the severity of vascular 
lesions (0-3), alveolar lesions (0-3), and lesions of larger airways (0-3).  
Phosphotungstic acid haematoxylin (PTH) staining was performed on lung 
sections to assess fibrin deposition. 
Quantitative Polymerase Chain  
Reaction for Gene Expression 
 
 Tissues were homogenized in Trizol reagent (Invitrogen) by collaborators 
in Texas and shipped to the University of Northern Colorado in 1 mL aliquots.  
Two hundred microliters of chloroform was added to each sample and incubated 
at room temperature for 2.5 minutes.  Samples were then spun at 12,000 x g for 
15 minutes at 4° C.  The aqueous upper layer was removed and transferred to a 
fresh tube with an equal volume of 70% ethanol and mixed.  RNA purified over 
RNAeasy columns according to kit instructions (Qiagen).  Samples were bound 
to spin columns for 15 seconds at 8,000 x g at room temperature and then 
washed using kit buffers.  RNA was then eluted from columns using sterile 
Millipore water by spinning for 1 minute at 8,000 x g.  All RNA samples were 
stored at -80° C. 
 Reverse transcription PCR (RT-PCR) was performed using random 




uL of reaction buffer, 1 uL reverse transcriptase, and 10 uL of RNAse free water 
(all provided by the kit manufacturer.)  Samples were then reverse transcribed 
into cDNA using a Bio-Rad thermocycler using the following conditions: 25°C for 
5 minutes, 42°C for 30 minutes, and 85°C for 5 minutes.  Samples were kept 
frozen at -20°C until used.   
 The cDNA generated was used for quantitative real time PCR using 
primers listed in Appendix D.  The protocol for the quantitative PCR assay was 
adapted from a previously established protocol (Oko et al., 2006).  Thirty-nine 
microliters of the cDNA was mixed with 487.5 uL of Millipore water and 487.5 
SYBR Green reaction mix.  Aliquots of 78 uL were added to deep well dishes and 
3 uL of primer was added.  Twenty-five microliters of mixture were then 
transferred into real time plates in triplicate.  Experiments were performed using 
the iQ SYBR Green kit for 50 cycles (45 seconds at 94°C, 50 seconds at 54°C, 
and 60 seconds at 72°C) in a MyiQ real time thermal cycler (Bio-Rad).  Cycle 
threshold values were calculated by averaging the relative fluorescence unit from 
cycles 10-14, +3 standard deviations.  Values were considered positive when 
they reached this value and were continuously 20% over previous values.  Fold 
expression was calculated using the delta delta Ct method. 
Aim 3 
Reverse Transcription Quantitative  
Polymerase Chain Reaction to  
Evaluate Viral Copy Number 
 Tissues were homogenized in Trizol reagent (Invitrogen) by collaborators 




Two hundred microliters of chloroform was added to each sample and incubated 
at room temperature for 2.5 minutes.  Samples were then spun at 12,000 x g for 
15 minutes at 4° C.  The aqueous upper layer was removed and transferred to a 
fresh tube with an equal volume of 70% ethanol and mixed.  RNA purified over 
RNAeasy columns according to kit instructions (Qiagen).  Samples were bound 
to spin columns for 15 seconds at 8,000 x g at room temperature and then 
washed using kit buffers.  RNA was then eluted from columns using sterile 
Millipore water by spinning for 1 minute at 8,000 x g.  All RNA samples were 
stored at -80° C. 
 Samples were quantified using a Nanodrop 2000 spectrophotometer and 
500 ng of RNA was used for reverse transcription.  Samples were reverse 
transcribed using a qScript kit with random hexamers and a single strand primer 
for either the negative (5'- TGTTATCCACAAGAGGGAGACAGAC -3’) or plus (5’-
CCTATCCATCCAGTCCTTCACAAAG-3’) strand of MAPV.  Five microliters of 
cDNA was removed and used in real-time PCR with the iQ SYBR green kit under 
the following conditions: 95°C for 10 min, followed by 40 cycles  of 95°C for 10 s, 
50°C for 10 s, and 72° C for 30 s.  A standard curve was generated using 100-
fold dilutions of MAPV from 107 to 70 copies.  
Statistical Analysis 
 Gene expression was evaluated using Prism GraphPad software. 
Significance was calculated using one way ANOVA followed by a Tukey post 
test.  A p-value < 0.05 was considered significant.  Data tables may be found in 














Aim 1: Infected and Uninfected Control Animals 
 
 The spleens of infected animals had significant increases (p<0.05) in 
interferon related genes Stat1 and Mx2; however, some were significant on day 8 
but not on 10 and vice versa (see Figure 1).  Pro-inflammatory gene IL-6 was 
also increased as were chemokine CXCL10, cyclin kinase inhibitor p27, and 
eukaryotic translation initiation factor (Eif2ak2).  Other pro-inflammatory genes 
























































































Figure 1.  Gene expression from spleens of hamsters infected with MAPV. 
Several pro-inflammatory genes were increased in infected animals compared to 
controls.  Significance is noted by an asterisk (*). 
 
 
Lung tissue from infected animals had significant differences in CXCL10. Stat1 
and Stat1b were all elevated compared to controls.  Many pro-inflammatory 




























































































Figure 2.  Gene expression from lungs of hamsters infected with MAPV.  Several 
pro-inflammatory genes were increased in infected animals, although none were 
considered statistically significant. 
 
 
Aim 2: Pathology 
 There was no difference in survival between animals treated with TGFβ1 
or IL-10 versus controls (see Figure 3).  There was a difference in lung 
congestion between treated and control animals.  The lungs from hamsters 
treated with TGFβ1 were thin, pink, and had less lung congestion; the volume of 
pleural fluid recovered from thoracic cavities was significantly less than controls 







Figure 3.  Survival curve of hamsters infected with MAPV and treated with 
TGFβ1 or IL-10.  Animals infected with MAPV and treated with either TGFβ1 or 
IL-10 did not have a significant difference in survival time compared to animals 







Figure 4.  Average pleural fluid from lungs hamsters infected with MAPV and  
treated with TGFβ1 or IL-10.  The average amount of pleural fluid recovered from 
the pleural cavity of animals infected with MAPV and treated with a PBS control 
was 3.75mL.  In animals treated with TGFβ1, there was a significant decrease in 
the fluid recovered (1.4mL).  In animals treated with IL-10, there was no 
significant decrease in pleural fluid recovered. 
 
 Lung sections were examined and scored for lesion severity (see Figure 
5).  Histopathologic changes in the lungs of MAPV infected animals were 
characterized by diffuse, mild expansion of alveolar septa by infiltrating 
inflammatory cells consisting of lymphocytes, macrophages, and fewer 
neutrophils (see Figure 5).  Alveoli contained increased numbers of alveolar 
macrophages with abundant foamy cytoplasm, occasional neutrophils, and areas 
of edema and hemorrhage. Alveolar walls appeared largely intact and hyaline 




























received IL-10, where they were more abundant and frequently positive for 
Phosphotungstic acid haematoxylin (PTH).  There was prominent perivascular 
edema with large accumulations of lymphocytes and macrophages with fewer 
neutrophils surrounding congested, small, medium, and large pulmonary vessels. 
Vessels frequently contained large number of neutrophils pavemented on the 
luminal surfaces.  Occasionally, medium sized vessel walls were expanded and 
disrupted by inflammatory cells and nuclear debris, but none contained PTH 
positive material within the walls. There was regional mesothelial cell hypertrophy 



















Figure 6. Histologic lung sections from hamsters infected with MAPV. Histologic 
lung sections are from Syrian hamsters on day 12 post- inoculation: (a) Normal 
Lung. Uninfected, untreated control animal. (b) There is interstitial and 
perivascular infiltration of lymphocytes, histiocytes and fewer neutrophils with 
minimal accumulations of edema and inflammatory cells within alveoli. MAPV 
infected, untreated animal.  (c) Histopathologic features are similar to (b). MAPV 
infected, TGF- treated animal.  (d) MAPV infected, IL-10 treated animal. 
Alveolar accumulations of edema, fibrin and inflammatory cells, mainly consisting 
of alveolar histiocytes and neutrophils, are greater when compared to (b) and (c). 
MAPV infected, IL-10 treated animal. (Hematoxylin and Eosin, Bar (a-d) = 






Figure 7.  Histologic sections of pulmonary vessels from hamsters infected with 
MAPV.  Histologic sections of medium-sized pulmonary vessels are from Syrian 
hamsters on day 12 post-inoculation. (a) Normal pulmonary vein.  Uninfected, 
untreated control animal. (b) Infiltrating lymphocytes, histiocytes and fewer 
neutrophils are restricted to the tunic adventicia and adjacent perivascular tissue. 
MAPV infected, untreated control animal.  (c) The Perivascular inflammation is 
similar to (b). MAPV infected, TGF- treated animal.  (d) Large numbers of 
inflammatory cells are present both within the inner tunics of the vessel wall 
(arrows) and surrounding it. MAPV infected, IL-10 treated animal.  (Hematoxylin 





 Collectively, there was considerable variation in lesion severity amongst 
individual animals within groups. Two of the three IL-10 treated hamsters had the 
most severe histologic changes.  MAPV-infected, TGF1 treated animals did not 
differ in lesion severity from those untreated MAPV-infected animals.  There were 
no appreciable histologic differences between cytokine treated uninfected 
animals when compared to uninfected controls.  However, one of the IL-10 
treated animals closely resembled controls; it may be questioned whether the 
pump functioned properly.  The lungs were only slightly congested and there was 
no pleural fluid.   
 Histopathologic changes in the spleen were mainly confined to the 
periartiolar lymphoid sheaths (PALs) in which there were mildly increased 
cellularity and prominence of follicular germinal centers in MAPV-infected 
animals (see Figure 8).  Two of the animals from the TGF1 group had spleens 
1.5-2 times the normal size and both of these animals survived.  Within affected 
follicles, there were increased numbers of large lymphocytes with frequent mitotic 
figures, increased numbers of tingible body macrophages, and lymphocytes 
undergoing apoptosis.  No significant changes were observed in the marginal 
zone or sinus.  Changes were present within the red pulp, namely lymphocyte 






Figure 8.  Histologic sections of spleen from hamsters infected with MAPV.  
Histologic sections of spleen are from Syrian hamsters on day 12 post-
inoculation. (a) Normal periartiolar lymphoid sheath and follicle (germinal center 
denoted by asterisk) surrounding artery (A), Uninfected, untreated control animal. 
(b) There is expansion of the germinal center by proliferating large lymphocytes 
with multiple mitotic figures (arrows) as well as lymphocytes undergoing 
apoptosis (arrowheads). MAPV infected, untreated control animal.  (c) The 
section contains features similar to (b). MAPV infected, TGF- treated animal.  
(d) Note the increased numbers of lymphocytes undergoing apoptosis (arrow) 
and the less well-defined germinal center when compared to (b or c). MAPV 




 There were mildly increased numbers of hematopoietic cells within the red 
pulp of infected animals.  Spleens from cytokine treated uninfected animals 
resembled those from control animals.  There were no appreciable differences 
between MAPV infected TGFβ1 treated and untreated MAPV infected animals.  
Two of three MAPV-infected, IL-10 treated animals had proportionally greater 
numbers of apoptotic cells within the PALs.  
Quantitative Polymerase Chain  
Reaction for Gene Expression 
 
 The spleens of TGFβ1 treated animals had a significant difference in IL-13 
expression level compared to controls which was increased.  There were no 
significant differences in gene expression in the lungs.  The IL-10 treatment 
group had elevated expression of several genes in the spleen as well as in the 
lung.  However, only IL-13 was statistically significant (see Figures 9 and 10).  














Gene expression from lungs of hamsters infected with  MAPV




























































Figure 9.  Gene expression from lungs of hamsters infected with MAPV. Although 
there were wide increases in gene expression for immune cytokines from lungs 





Gene expression from spleens of hamsters infected with




























































Figure 10.  Gene expression from spleens of hamsters infected with MAPV.  
Several immune genes from spleens of infected hamsters treated with TGFβ1 
were significantly different from infected, untreated control animals.  None were 
statistically significant in the IL-10 treatment group. 
 
 
Aim 3: Viral Copy Number 
 
 Viral copy number was evaluated in tissues from control animals and 
those treated with TGFβ1 or IL-10.  Both positive and negative strand viral RNA 
were detected in the lungs of three of the five animals infected with MAPV and 
treated with TGFβ1; no significance difference was noted between the positive 
and negative strands (see Figure 11).  Viral copy numbers were similar in 
animals treated with IL-10 (two of three animals examined had detectable viral 
RNA) and no significance difference was observed.  All standard curves 
produced a 0.89 correlations or better between the relative fluorescence value 









































Figure 11.  Viral copy number in lungs of infected hamsters.  Viral copy number 
was evaluated in three hamsters infected with MAPV.  There was no significant 
difference in copy number between positive and negative strand.  There was also 
no difference in copy numbers between the TGFβ1 and IL-10 treated groups (not 


















 This is the first time gene expression has been evaluated in the hamster 
HCPS model.  Unfortunately, there are no hamster specific reagents that can 
evaluate protein expression.  Instead, we utilized available sequences to 
measure gene expression using real-time PCR.  Results presented here suggest 
that HCPS is not mediated by pro-inflammatory cytokines in the hamster model, 
dissimilar to human disease. 
 Gene expression studies demonstrated an obvious lack of elevation in 
inflammatory cytokines such as TNF and IFNγ.  Data of gene expression from 
infected human tissues are limited.  Mori et al. (1998) used 
immunohistochemistry to evaluate cytokine levels in human autopsy sections and 
described significant increases in TNF and IFNγ staining in lungs.  Our panel of 
genes investigated in the hamster model was larger than that evaluated with IHC; 
we observed increases in other cytokines that implicated innate mechanisms 
rather than T cell mediated disease, e.g., transcription factors STAT1 and 
STAT1b, which are part of the interferon signaling system.  We also observed an 




plausible that IFNγ is elevated at earlier time points than evaluated here and 
functions to increase expression of CXCL10.   
 Our studies support those of Hammerbeck and Hooper (2011) that HCPS 
may not be a T cell mediated disease in the hamster model.  In their study using 
ANDV in the hamster model, T cells were activated at disease onset; however, 
when T cell function was blocked by cyclophosamide, there was similar disease 
pathology.  This may indicate that the (T cell specific) cytokines observed in 
HCPS may not be the sole cause of pathology.  The T cell responses that did 
occur appeared to be predominately CD8+ T cells (Lindgren et al., 2011).    
Aim 2 
 Deer mice with persistent infection of SNV develop increased gene 
expression of TGFβ1 as do Norway rats infected with Seoul hantavirus 
(Easterbrook et al., 2007; Schountz et al., 2007).  Because of this, we postulated 
the anti-inflammatory activity of TGFβ1 might be essential in the reservoir not 
developing pathology.  Because IL-10 and TGFβ1 are both potent anti-
inflammatory molecules that may be secreted from T regulatory cells, IL-10 was 
also investigated.  Here we demonstrated that TGFβ1 might benefit hamsters 
infected with Maporal hantavirus while IL-10 augmented disease pathology. 
TGFβ1 treated hamsters had decreased pleural fluid and congestion, although 
lesion severity scores closely resembled infected, untreated control animals.  The 
lungs of IL-10 treated animals had severe histological changes, including edema 
and more inflammatory cells, compared to TGFβ1 and control groups.  This 




statistically significant, the authors believe they were still meaningful due to the 
unpredictable natures of using whole animals in experiments rather than in vitro 
work with cells.  A study by Maganto-Garcia et al. (2011) demonstrated the ability 
of TGFβ1 to suppress endothelial cell activation in heart tissue; however, IL-10 
was not included in this study.   
 The increase in IL-13 in the spleens of infected and treated animals was 
suggestive of a Th2 involvement.  IL-13 and IL-4 are usually observed influencing 
T cells to differentiate into a Th2 response and may be secreted by tissue 
macrophages during inflammatory responses.  In TGFβ1 treated animals, there 
were no significant changes observed in the marginal zone or sinus.  Changes 
were present within the red pulp, namely lymphocyte apoptosis, but this was also 
present in the uninfected controls; in all likelihood, this represented a stress 
response that may have been simply exacerbated by infection in some animals.  
In contrast, IL-10 treated animals had an increase in the number of cells 
undergoing apoptosis in a less well defined germinal center, which may be 
indicative of a more severe disease.  This group also had a significant increase in 
lesion scores in the spleen compared to infected control animals. 
 TGFβ1 is a pleiotropic cytokine that can have both pro-fibrotic and 
immunosuppressive actions.  Several therapeutics involving TGFβ1 were 
formulated to limit its action and thus ameliorated fibrotic diseases such as 
glomerulosclerosis.  Because of TGFβ1 adverse effects, it has not been actively 




 However, in studies with viral infections, TGFβ1 administration may have 
some therapeutic benefit.  In cases of DHF, high levels of TGFβ1 have been 
associated with less severe pathology (Perez et al., 2010; Sierra et al., 2010).  
However, the level of IL-10 in these studies was associated with more severe 
DHF; this severity correlated with specific polymorphisms in the IL-10 gene 
(Perez et al., 2010; Sierra et al., 2010).  Patients infected with Dobrava 
hantavirus (which causes HFRS) also had significantly elevated levels of IL-10 as 
measured by ELISA.  This level of IL-10 correlated with disease severity (higher 
levels of IL-10 were associated with more severe disease; Saksida, Wraber, & 
Avsic-Zupancic, 2011). 
  Human lung fibroblasts pretreated with TGFβ1 were more susceptible to 
rhinovirus infection and replication; myofibroblasts have deceased type I 
interferon responses as measured by ISGs RANTES and IP-10 (Thomas et al., 
2009).  Hence, TGFβ1 may be helping cells to subvert the interferon response.  
This, in turn, allows for increased viral replication while also delaying an 
inflammatory response, which has also been the suggested role in deer mice 
infected with SNV. 
   The interferon response to pathogenic hantavirus in humans appears to 
be disrupted, perhaps by a part of the nucleocapsid or glycoprotein (Alff et al., 
2006; Prescott et al., 2005).  Endothelial cells infected with HCPS-causing 
viruses have augmented ISG expression compared to cells with non-pathogenic 
hantavirus (Alff et al., 2006; Prescott et al., 2005).  Because IL-10 also uses the 




somehow interfering with the Jak/Stat signaling and leading to disease 
attenuation.  In a study with Dengue virus (Ubol, Phuklia, Kalayanarooj, & 
Modhiran, 2010), it was observed that increased levels of IL-10 activated 
expression of suppressor of cytokine signal 3, limiting the Jak/Stat pathway.  
Pathogenic virus may then take advantage of this suppression to promote their 
own survival.  Our results correlated with this as we did not observe a significant 
increase in interferon α or β.  Interestingly, it was impossible to obtain any 
statistical significance with either IL-10 or TGFβ1 treatments.  Both groups had 
similar amounts of genomic and anti-genomic viral copies in the lungs of infected 
animals, indicating that the type of treatment did not affect viral burden.   
 This study demonstrated that TGFβ1 might improve the outcome for 
hamsters infected with MAPV.  Because only little improvement was noted, future 
directions might include a higher dosage of TGFβ1.  It appeared clear that IL-10 
would be of no therapeutic benefit.  Because of the use of Andes as a model of 
HCPS, it might also be suggested to study TGFβ1 in hamsters infected with this 
virus.  This study used only the few cytokine sequences that were available.  
Since then, many more hamster sequences have become available and should 
be included in further studies. 
Statistical Analysis 
 To evaluate significance of gene expression studies and lesion scores, 
one way ANOVA statistical tests were conducted for each gene.  This enabled 
the means to be compared between each of the groups and reduced the risk of 




evaluate gene expression studies.  One potential problem with this study was the 
limited amount of animals.  This might be a reason for R values lower than 
desired in our results.  However, due to costs and time constraints, the author 
was limited in the number of animals that could be used and could not perform 
repeated studies. 
 A Tukey-Kramer post hoc test was also utilized to compare each mean 
with the others.  Using this test helped decrease the likelihood Type I and II 
errors were made.   
 Such tests also assumed that the population of animals used in these 
studies was a random representation of Syrian golden hamsters.  In fact, this 
might not be true.  Colonies of hamsters were developed using only a few wild 
caught animals.  Hence, these animals might be more heavily inbred and not a 
true representation.  
Future Directions 
 This study sheds new light on a potential mechanism for hantavirus 
cardiopulmonary pathogenesis.  It was hypothesized that the virus entered via 
the respiratory route and infected endothelial cells.  The virus then modulated the 
interferon response while it replicated itself and was released into the intra-
alveolar space, where it might infect or be engulfed by alveolar macrophages.  
This allowed the virus to be disseminated to other organs of the body, namely the 
spleen.  It is plausible that there was an interaction between macrophages and T 
cells that induced the production of IFNγ, which then acted to increase the 




 In vitro studies suggested that after three days post-infection, cells were 
able to develop a more robust type I interferon response (Prescott et al., 2005), 
while earlier time points had decreased levels of interferons and interferon 
response genes compared to non-pathogenic hantaviruses (Spiropoulou, 
Albarino, Ksiazek, & Rollin, 2007).  Hence, we hypothesized that initially the virus 
suppressed the interferon response and disseminated throughout the body.  After 
a few days, infected cells overcame the virus but developed a modified interferon 
response.  After the virus infected the macrophages, they traveled to the spleen, 
replicated further, and presented antigen in the MHC-I complex to CD4+ and 
CD8+ T cells. 
 A recent study suggests a role for vascular endothelial growth factor 
(VEGF) and cadherin.  Human pulmonary endothelial cells infected with Andes 
hantavirus increased expression of VEGF that coincided with a decrease in 
cadherin.  This protein is known to play a major role in the adherens junctions of 
endothelial membranes.  Endothelial cells infected with Andes also had disrupted 
cell membranes and evidence of increased permeability.  Due to the lack of 
observed TNF in these studies, it was also hypothesized that the pulmonary 
edema seen in HCPS victims was due to deregulation of VEGF and cadherin 
rather than a cytokine storm as originally hypothesized. 
 A major pitfall of the hamster model was there are no antibody reagents 
that are cross-reactive in hamsters; thus, it is unknown if some of the cytokines 




 To study any disease, it is necessary to use an animal model that 
presents with a similar disease seen in humans.  Pathologically, the hamster 
appears to be a useful model.  However, few reagents are cross reactive with 
hamster proteins.  Antibodies that are useful in rat and mouse models are not 
cross reactive in the hamster or the deer mouse.  This limits scientists to gene 
expression studies.  The entire genome has not been sequenced in both animals 
so many genes are still unavailable.   
 One of the most useful tools would be the development of antibodies 
against T cell subsets, macrophages, and endothelial cells.  With these tools, 
immunohistochemistry could be performed evaluating not only organ lesions but 
the cellular component of these lesions would also be known.  This could give 
researchers insight into the immune mechanisms mediating the disease.  
Although such antibodies might also be used in flow cytometry, the use of a BSL-
4 virus in such a machine might not be practical for many labs. 
 In addition to better and a wider variety of reagents for use in the hamster 
model, it was also evident from the studies conducted here that gene expression 
should also be monitored at earlier time points.  This has been easily 
accomplished in cell culture systems but not in an animal model.  Our results 
supported evidence that many genes might have been expressed at earlier time 
points and were back to relatively normal levels by day 8.  This might explain why 
we did not observe an increase in TNF and/or IFNγ. 
 Although the deer mice had increased expression of TGFβ1 and Foxp3+ , 




animal models.  To better evaluate if this is indeed attenuating pathology in the 
host, the blocking the development of T regulatory cells with a drug such as 
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LIST OF SELECTED HANTAVIRUSES  





List of Selected Hantaviruses and  
Known Rodent Reservoirs 
Hantaan virus (HTNV)*  Apodemus agrarius  
Seoul virus (SEOV)*  Rattus norvegicus  
Dobrava-Belgrade virus (DOBV)*  A.flavicollis  
Puumala virus (PUUV)*  Myodes glareolus  
Sin Nombre virus (SNV)**  Peromyscus maniculatus  
New York virus (NYV)**  Peromyscus leucopus  
Bayou virus (BAYV)**  Oryzomys palustris  
Andes virus (ANDV)**  Oligoryzomys longicaudatus  
Maporal virus (MAPV)  Oligoryzomys fulvescens  
Prospect Hill virus (PHV)  Microtus pennsylvanicus  
Thottapalayam virus (TPMV)  Suncus murinus  
Tula virus (TULV)  Microtus arvalis  
* indicates known HFRS causing virus  
** indicates known HCPS causing virus.  Others are of unknown pathology. 
 
























Euthanasia Table Used to Evaluate Infected 
Hamsters on a Daily Basis 
 
Euthanasia Scoring Evaluation 
 
Animal:      Date:   Time:     
 
Animals will be evaluated twice daily. If a score of 1 or more is noted at any 
evaluation, animals will be observed thrice daily for disease progression. 
 
Eating/Drinking Normal amount of feces 





Behavior Normal nesting 





Movement* Normal when touched 
Reluctant to move when touched 
















Total   
 
Criteria for immediate euthanasia: 
A score of 5 or more in an evaluation 
Animals that are moribund or suffer 10% or more weight loss in an evaluation 
Visible hemorrhaging in an evaluation 
Any animal in groups denoted with an ‘*’ with a score of 2 in two consecutive 
evaluations 



















Primers Used for Real Time PCR--RPL18 
 
 
RPL18 was used as a negative control in gene expression experiments.  Primers developed by 
















Primers Used For Real Time PCR--GAPDH 
 



















ANOVA TABLES FOR INFECTED VERSUS 




Study K006 Lung Tissue ANOVA Tables from qPCR Experiments 
Parameter      
Table Analyzed IFNgamma     
      
One-way analysis of variance      
  P value 0.0447     
  P value summary *     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 5.007     
  R square 0.5886     
      
ANOVA Table SS df MS   
  Treatment (between columns) 124.6 2 62.31   
  Residual (within columns) 87.11 7 12.44   
  Total 211.7 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IFNg vs IL10 7.333 3.601 No ns -1.149 to 15.82 
  IFNg vs TGF -0.6125 0.3215 No ns -8.547 to 7.322 







Parameter      
Table Analyzed IL1alpha     
      
One-way analysis of variance      
  P value 0.5197     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.7197     
  R square 0.1706     
      
ANOVA Table SS df MS   
  Treatment (between columns) 14.38 2 7.191   
  Residual (within columns) 69.94 7 9.991   
  Total 84.32 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IL1a vs IL10 2.777 1.522 No ns -4.824 to 10.38 
  IL1a vs TGF 0.3050 0.1787 No ns -6.805 to 7.415 








Parameter      
Table Analyzed IL1beta     
      
One-way analysis of variance      
  P value 0.8383     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.1809     
  R square 0.04916     
      
ANOVA Table SS df MS   
  Treatment (between columns) 3.476 2 1.738   
  Residual (within columns) 67.24 7 9.606   
  Total 70.72 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Il1ß vs IL10 1.333 0.7451 No ns -6.120 to 8.786 
  Il1ß vs TGF 1.248 0.7453 No ns -5.724 to 8.219 






Parameter      
Table Analyzed IL2     
      
One-way analysis of variance      
  P value 0.5633     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.6238     
  R square 0.1513     
      
ANOVA Table SS df MS   
  Treatment (between columns) 13.34 2 6.669   
  Residual (within columns) 74.84 7 10.69   
  Total 88.18 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IL2 vs IL10 0.8933 0.4732 No ns -6.969 to 8.756 
  IL2 vs TGF -1.803 1.021 No ns -9.157 to 5.552 








Parameter      
Table Analyzed IL4     
One-way analysis of variance      
  P value 0.5638     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.6225     
  R square 0.1510     
      
ANOVA Table SS df MS   
  Treatment (between columns) 24.93 2 12.47   
  Residual (within columns) 140.2 7 20.02   
  Total 165.1 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IL4 vs IL10 3.000 1.161 No ns -7.760 to 13.76 
  IL4 vs TGF -0.6825 0.2824 No ns -10.75 to 9.383 






Parameter      
Table Analyzed IL-6     
      
One-way analysis of variance      
  P value 0.7143     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.3531     
  R square 0.09164     
      
ANOVA Table SS df MS   
  Treatment (between columns) 11.47 2 5.734   
  Residual (within columns) 113.7 7 16.24   
  Total 125.1 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IL6 vs IL10 1.113 0.4785 No ns -8.577 to 10.80 
  IL6 vs TGF -1.444 0.6636 No ns -10.51 to 7.620 






Parameter      
Table Analyzed IL10     
      
One-way analysis of variance      
  P value 0.3812     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.110     
  R square 0.2408     
      
ANOVA Table SS df MS   
  Treatment (between columns) 35.34 2 17.67   
  Residual (within columns) 111.4 7 15.91   
  Total 146.7 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IL10 vs IL10 4.780 2.075 No ns -4.813 to 14.37 
  IL10 vs TGF 1.724 0.8003 No ns -7.249 to 10.70 








Parameter      
Table Analyzed IL12     
      
One-way analysis of variance      
  P value 0.3516     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.218     
  R square 0.2582     
      
ANOVA Table SS df MS   
  Treatment (between columns) 21.19 2 10.59   
  Residual (within columns) 60.89 7 8.698   
  Total 82.08 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IL12 vs IL10 3.670 2.155 No ns -3.422 to 10.76 
  IL12 vs TGF 1.194 0.7497 No ns -5.440 to 7.828 







Parameter      
Table Analyzed IL13     
      
One-way analysis of variance      
  P value 0.3585     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.192     
  R square 0.2541     
      
ANOVA Table SS df MS   
  Treatment (between columns) 59.51 2 29.75   
  Residual (within columns) 174.7 7 24.96   
  Total 234.2 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IL13 vs IL10 5.447 1.888 No ns -6.567 to 17.46 
  IL13 vs TGF 0.2225 0.08247 No ns -11.02 to 11.46 







Parameter      
Table Analyzed MHC-I     
      
One-way analysis of variance      
  P value 0.1480     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 2.541     
  R square 0.4207     
      
ANOVA Table SS df MS   
  Treatment (between columns) 38.22 2 19.11   
  Residual (within columns) 52.64 7 7.520   
  Total 90.86 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  MHC-I vs IL10 2.553 1.613 No ns -4.041 to 9.147 
  MHC-I vs TGF 4.719 3.187 No ns -1.449 to 10.89 







Parameter      
Table Analyzed MHC-II     
      
One-way analysis of variance      
  P value 0.2569     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.660     
  R square 0.3218     
      
ANOVA Table SS df MS   
  Treatment (between columns) 24.46 2 12.23   
  Residual (within columns) 51.56 7 7.365   
  Total 76.02 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  MHC-II vs IL10 3.330 2.125 No ns -3.196 to 9.856 
  MHC-II vs TGF 3.471 2.368 No ns -2.634 to 9.575 








Parameter      
Table Analyzed TGF     
      
One-way analysis of variance      
  P value 0.5684     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.6132     
  R square 0.1491     
      
ANOVA Table SS df MS   
  Treatment (between columns) 6.526 2 3.263   
  Residual (within columns) 37.25 7 5.321   
  Total 43.78 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  TGFß1 vs IL10 1.890 1.419 No ns -3.657 to 7.437 
  TGFß1 vs TGF 1.643 1.318 No ns -3.546 to 6.831 








Parameter      
Table Analyzed TNF     
      
One-way analysis of variance      
  P value 0.4032     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.037     
  R square 0.2286     
      
ANOVA Table SS df MS   
  Treatment (between columns) 20.17 2 10.08   
  Residual (within columns) 68.06 7 9.723   
  Total 88.23 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  TNF vs IL10 3.667 2.037 No ns -3.832 to 11.16 
  TNF vs TGF 1.864 1.107 No ns -5.150 to 8.878 






Study K006 Spleen Tissue Samples from qPCR 
Parameter      
Table Analyzed IFNgamma     
      
One-way analysis of variance      
  P value 0.3360     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.367     
  R square 0.3536     
      
ANOVA Table SS df MS   
  Treatment (between columns) 3.553 2 1.777   
  Residual (within columns) 6.497 5 1.299   
  Total 10.05 7    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IFNg vs IL10 1.665 2.066 No ns -2.044 to 5.374 
  IFNg vs TGF 1.458 2.088 No ns -1.755 to 4.670 






Parameter      
Table Analyzed IL1alpha     
      
One-way analysis of variance      
  P value 0.9967     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.003329     
  R square 0.001330     
      
ANOVA Table SS df MS   
  Treatment (between columns) 0.03084 2 0.01542   
  Residual (within columns) 23.16 5 4.632   
  Total 23.19 7    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IL1a vs IL10 0.1650 0.1084 No ns -6.838 to 7.168 
  IL1a vs TGF 0.04000 0.03035 No ns -6.025 to 6.105 








Parameter      
Table Analyzed IL1beta     
      
One-way analysis of variance      
  P value 0.0781     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 4.431     
  R square 0.6393     
      
ANOVA Table SS df MS   
  Treatment (between columns) 4.589 2 2.295   
  Residual (within columns) 2.589 5 0.5179   
  Total 7.179 7    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Il1ß vs IL10 1.830 3.596 No ns -0.5118 to 4.172 
  Il1ß vs TGF 1.703 3.863 No ns -0.3256 to 3.731 








Parameter      
Table Analyzed IL2     
      
One-way analysis of variance      
  P value 0.3580     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.270     
  R square 0.3369     
      
ANOVA Table SS df MS   
  Treatment (between columns) 3.938 2 1.969   
  Residual (within columns) 7.749 5 1.550   
  Total 11.69 7    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IL2 vs IL10 1.830 2.079 No ns -2.221 to 5.881 
  IL2 vs TGF 1.458 1.912 No ns -2.051 to 4.966 






Parameter      
Table Analyzed IL4     
      
One-way analysis of variance      
  P value 0.4476     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.9483     
  R square 0.2750     
      
ANOVA Table SS df MS   
  Treatment (between columns) 5.606 2 2.803   
  Residual (within columns) 14.78 5 2.956   
  Total 20.39 7    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IL4 vs IL10 1.505 1.238 No ns -4.090 to 7.100 
  IL4 vs TGF 2.045 1.942 No ns -2.800 to 6.890 






Parameter      
Table Analyzed IL6     
      
One-way analysis of variance      
  P value 0.1920     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 2.337     
  R square 0.4832     
      
ANOVA Table SS df MS   
  Treatment (between columns) 6.708 2 3.354   
  Residual (within columns) 7.176 5 1.435   
  Total 13.88 7    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IL6 vs IL10 2.335 2.756 No ns -1.563 to 6.233 
  IL6 vs TGF 1.960 2.672 No ns -1.416 to 5.336 








Parameter      
Table Analyzed IL10     
      
One-way analysis of variance      
  P value 0.0817     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 4.309     
  R square 0.6329     
      
ANOVA Table SS df MS   
  Treatment (between columns) 8.806 2 4.403   
  Residual (within columns) 5.109 5 1.022   
  Total 13.92 7    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IL10 vs IL10 2.335 3.267 No ns -0.9544 to 5.624 
  IL10 vs TGF 2.463 3.978 No ns -0.3862 to 5.311 








Parameter      
Table Analyzed IL12     
      
One-way analysis of variance      
  P value 0.1324     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 3.112     
  R square 0.5545     
      
ANOVA Table SS df MS   
  Treatment (between columns) 7.207 2 3.604   
  Residual (within columns) 5.790 5 1.158   
  Total 13.00 7    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IL12 vs IL10 2.165 2.845 No ns -1.337 to 5.667 
  IL12 vs TGF 2.205 3.346 No ns -0.8275 to 5.238 






Parameter      
Table Analyzed IL13     
      
One-way analysis of variance      
  P value 0.0175     
  P value summary *     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 10.12     
  R square 0.8019     
      
ANOVA Table SS df MS   
  Treatment (between columns) 18.69 2 9.347   
  Residual (within columns) 4.619 5 0.9238   
  Total 23.31 7    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IL13 vs IL10 3.505 5.157 Yes * 0.3774 to 6.633 
  IL13 vs TGF 3.543 6.019 Yes * 0.8339 to 6.251 





Parameter      
Table Analyzed MHC-I     
      
One-way analysis of variance      
  P value 0.0597     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 5.218     
  R square 0.6761     
      
ANOVA Table SS df MS   
  Treatment (between columns) 15.15 2 7.577   
  Residual (within columns) 7.260 5 1.452   
  Total 22.41 7    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  MHC-I vs IL10 3.500 4.108 No ns -0.4212 to 7.421 
  MHC-I vs TGF 2.955 4.005 No ns -0.4409 to 6.351 








Parameter      
Table Analyzed MHC-II     
      
One-way analysis of variance      
  P value 0.2182     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 2.096     
  R square 0.4560     
      
ANOVA Table SS df MS   
  Treatment (between columns) 7.720 2 3.860   
  Residual (within columns) 9.209 5 1.842   
  Total 16.93 7    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  MHC-II vs IL10 0.8300 0.8649 No ns -3.586 to 5.246 
  MHC-II vs TGF 2.290 2.755 No ns -1.535 to 6.115 






Parameter      
Table Analyzed TGF     
      
One-way analysis of variance      
  P value 0.1800     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 2.464     
  R square 0.4964     
      
ANOVA Table SS df MS   
  Treatment (between columns) 5.550 2 2.775   
  Residual (within columns) 5.631 5 1.126   
  Total 11.18 7    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  TGFß1 vs IL10 1.330 1.772 No ns -2.123 to 4.783 
  TGFß1 vs TGF 2.040 3.139 No ns -0.9508 to 5.031 





Parameter      
Table Analyzed TNF     
      
One-way analysis of variance      
  P value 0.0608     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 5.163     
  R square 0.6737     
      
ANOVA Table SS df MS   
  Treatment (between columns) 8.665 2 4.332   
  Residual (within columns) 4.196 5 0.8392   
  Total 12.86 7    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  TNF vs IL10 1.835 2.833 No ns -1.146 to 4.816 
  TNF vs TGF 2.545 4.537 No ns -0.03659 to 5.127 

















ANOVA TABLES FOR TREATED VERSUS 




Study L005 Lung ANOVA tables from qPCR 
Parameter      
Table Analyzed ANOVA IL1b     
      
One-way analysis of variance      
  P value 0.6129     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.5546     
  R square 0.2171     
      
ANOVA Table SS df MS   
  Treatment (between columns) 2.357 2 1.179   
  Residual (within columns) 8.500 4 2.125   
  Total 10.86 6    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 1.500 1.455 No ns -3.695 to 6.695 
  Control vs Day 10 0.5000 0.5314 No ns -4.242 to 5.242 







Parameter      
Table Analyzed Bax     
      
One-way analysis of variance      
  P value 0.2397     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.764     
  R square 0.3351     
      
ANOVA Table SS df MS   
  Treatment (between columns) 12.60 2 6.300   
  Residual (within columns) 25.00 7 3.571   
  Total 37.60 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -1.500 1.296 No ns -6.320 to 3.320 
  Control vs Day 10 -2.500 2.646 No ns -6.436 to 1.436 








Parameter      
Table Analyzed Bcl-2     
      
One-way analysis of variance      
  P value 0.0628     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 4.219     
  R square 0.5466     
      
ANOVA Table SS df MS   
  Treatment (between columns) 55.75 2 27.88   
  Residual (within columns) 46.25 7 6.607   
  Total 102.0 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -3.250 2.065 No ns -9.806 to 3.306 
  Control vs Day 10 -5.250 4.085 No ns -10.60 to 0.1029 








Parameter      
Table Analyzed CC3d     
      
One-way analysis of variance      
  P value 0.1729     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 2.385     
  R square 0.4429     
      
ANOVA Table SS df MS   
  Treatment (between columns) 27.56 2 13.78   
  Residual (within columns) 34.67 6 5.778   
  Total 62.22 8    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 4.667 3.008 No ns -2.066 to 11.40 
  Control vs Day 10 2.667 2.054 No ns -2.966 to 8.299 







Parameter      
Table Analyzed CC5     
      
One-way analysis of variance      
  P value 0.2808     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.581     
  R square 0.3452     
      
ANOVA Table SS df MS   
  Treatment (between columns) 25.39 2 12.69   
  Residual (within columns) 48.17 6 8.028   
  Total 73.56 8    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -1.833 1.002 No ns -9.769 to 6.102 
  Control vs Day 10 -3.833 2.505 No ns -10.47 to 2.806 








Parameter      
Table Analyzed CCL17     
      
One-way analysis of variance      
  P value 0.3189     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.352     
  R square 0.2786     
      
ANOVA Table SS df MS   
  Treatment (between columns) 43.35 2 21.68   
  Residual (within columns) 112.3 7 16.04   
  Total 155.6 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -4.250 1.733 No ns -14.46 to 5.964 
  Control vs Day 10 -4.250 2.123 No ns -12.59 to 4.089 








Parameter      
Table Analyzed CCL22     
      
One-way analysis of variance      
  P value 0.1183     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 2.940     
  R square 0.4565     
      
ANOVA Table SS df MS   
  Treatment (between columns) 87.15 2 43.58   
  Residual (within columns) 103.8 7 14.82   
  Total 190.9 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -5.500 2.333 No ns -15.32 to 4.319 
  Control vs Day 10 -6.250 3.247 No ns -14.27 to 1.767 






Parameter      
Table Analyzed CD83     
      
One-way analysis of variance      
  P value 0.0022     
  P value summary **     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 16.70     
  R square 0.8267     
      
ANOVA Table SS df MS   
  Treatment (between columns) 75.15 2 37.58   
  Residual (within columns) 15.75 7 2.250   
  Total 90.90 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -5.250 5.715 Yes * -9.076 to -1.424 
  Control vs Day 10 -5.750 7.667 Yes ** -8.874 to -2.626 








Parameter      
Table Analyzed CXCL10     
      
One-way analysis of variance      
  P value 0.0154     
  P value summary *     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 9.049     
  R square 0.7510     
      
ANOVA Table SS df MS   
  Treatment (between columns) 41.22 2 20.61   
  Residual (within columns) 13.67 6 2.278   
  Total 54.89 8    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 5.667 5.817 Yes * 1.440 to 9.894 
  Control vs Day 10 1.167 1.431 No ns -2.370 to 4.703 








Parameter      
Table Analyzed Ecad     
      
One-way analysis of variance      
  P value 0.4489     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.9000     
  R square 0.2045     
      
ANOVA Table SS df MS   
  Treatment (between columns) 18.90 2 9.450   
  Residual (within columns) 73.50 7 10.50   
  Total 92.40 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -2.250 1.134 No ns -10.51 to 6.015 
  Control vs Day 10 -3.000 1.852 No ns -9.748 to 3.748 








Parameter      
Table Analyzed Foxp3     
      
One-way analysis of variance      
  P value 0.0128     
  P value summary *     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 8.669     
  R square 0.7124     
      
ANOVA Table SS df MS   
  Treatment (between columns) 96.60 2 48.30   
  Residual (within columns) 39.00 7 5.571   
  Total 135.6 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -6.000 4.151 No ns -12.02 to 0.02024 
  Control vs Day 10 -6.500 5.508 Yes * -11.42 to -1.584 







Parameter      
Table Analyzed ICAM1     
      
One-way analysis of variance      
  P value 0.5692     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.6114     
  R square 0.1487     
      
ANOVA Table SS df MS   
  Treatment (between columns) 10.35 2 5.175   
  Residual (within columns) 59.25 7 8.464   
  Total 69.60 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 2.750 1.544 No ns -4.670 to 10.17 
  Control vs Day 10 1.250 0.8593 No ns -4.809 to 7.309 








Parameter      
Table Analyzed IFNg     
      
One-way analysis of variance      
  P value 0.4978     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.7853     
  R square 0.2075     
      
ANOVA Table SS df MS   
  Treatment (between columns) 10.97 2 5.486   
  Residual (within columns) 41.92 6 6.986   
  Total 52.89 8    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -2.167 1.270 No ns -9.570 to 5.236 
  Control vs Day 10 -2.417 1.693 No ns -8.610 to 3.777 








Parameter      
Table Analyzed IL2     
      
One-way analysis of variance      
  P value 0.0065     
  P value summary **     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 13.05     
  R square 0.8131     
      
ANOVA Table SS df MS   
  Treatment (between columns) 365.0 2 182.5   
  Residual (within columns) 83.92 6 13.99   
  Total 448.9 8    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -7.833 3.245 No ns -18.31 to 2.641 
  Control vs Day 10 -14.58 7.220 Yes ** -23.35 to -5.820 






Parameter      
Table Analyzed IL2Ra     
      
One-way analysis of variance      
  P value 0.0026     
  P value summary **     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 15.65     
  R square 0.8172     
      
ANOVA Table SS df MS   
  Treatment (between columns) 115.2 2 57.58   
  Residual (within columns) 25.75 7 3.679   
  Total 140.9 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -7.250 6.173 Yes ** -12.14 to -2.358 
  Control vs Day 10 -6.750 7.039 Yes ** -10.74 to -2.756 








Parameter      
Table Analyzed IL-4     
      
One-way analysis of variance      
  P value 0.2121     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.951     
  R square 0.3579     
      
ANOVA Table SS df MS   
  Treatment (between columns) 30.10 2 15.05   
  Residual (within columns) 54.00 7 7.714   
  Total 84.10 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -4.250 2.499 No ns -11.33 to 2.834 
  Control vs Day 10 -3.000 2.160 No ns -8.784 to 2.784 








Parameter      
Table Analyzed IL6     
      
One-way analysis of variance      
  P value 0.5173     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.7372     
  R square 0.1973     
      
ANOVA Table SS df MS   
  Treatment (between columns) 2.806 2 1.403   
  Residual (within columns) 11.42 6 1.903   
  Total 14.22 8    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -1.333 1.497 No ns -5.197 to 2.530 
  Control vs Day 10 -1.083 1.454 No ns -4.316 to 2.149 








Parameter     
Table Analyzed IL-10    
     
One-way analysis of variance     
  P value 0.9725    
  P value summary ns    
  Are means signif. different? (P < 0.05) No    
  Number of groups 3    
  F 0.0280    
  R square 0.007937    
     
ANOVA Table SS df MS  
  Treatment (between columns) 0.1500 2 0.0750  
  Residual (within columns) 18.75 7 2.679  
  Total 18.90 9   
     
Newman-Keuls Multiple Comparison Test Mean Diff. q Significant? 
P < 0.05? Summary 
  Control vs Day 10 -0.2500 0.3055 No ns 
  Control vs Day 8 0.0 --- No ns 








Parameter      
Table Analyzed IL12p40     
      
One-way analysis of variance      
  P value 0.1128     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 3.029     
  R square 0.4639     
      
ANOVA Table SS df MS   
  Treatment (between columns) 70.75 2 35.38   
  Residual (within columns) 81.75 7 11.68   
  Total 152.5 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -5.750 2.748 No ns -14.47 to 2.966 
  Control vs Day 10 -5.250 3.073 No ns -12.37 to 1.867 








Parameter      
Table Analyzed IL12p40     
      
One-way analysis of variance      
  P value 0.1128     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 3.029     
  R square 0.4639     
      
ANOVA Table SS df MS   
  Treatment (between columns) 70.75 2 35.38   
  Residual (within columns) 81.75 7 11.68   
  Total 152.5 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -5.750 2.748 No ns -14.47 to 2.966 
  Control vs Day 10 -5.250 3.073 No ns -12.37 to 1.867 








Parameter      
Table Analyzed IL21     
      
One-way analysis of variance      
  P value 0.0125     
  P value summary *     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 8.742     
  R square 0.7141     
      
ANOVA Table SS df MS   
  Treatment (between columns) 141.8 2 70.88   
  Residual (within columns) 56.75 7 8.107   
  Total 198.5 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -6.000 3.441 No ns -13.26 to 1.262 
  Control vs Day 10 -8.250 5.795 Yes * -14.18 to -2.320 







Parameter      
Table Analyzed iNOS     
      
One-way analysis of variance      
  P value 0.7531     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.2953     
  R square 0.07782     
      
ANOVA Table SS df MS   
  Treatment (between columns) 6.350 2 3.175   
  Residual (within columns) 75.25 7 10.75   
  Total 81.60 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -0.5000 0.2490 No ns -8.862 to 7.862 
  Control vs Day 10 -1.750 1.067 No ns -8.578 to 5.078 








Parameter      
Table Analyzed IRF1     
      
One-way analysis of variance      
  P value 0.1644     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 2.363     
  R square 0.4030     
      
ANOVA Table SS df MS   
  Treatment (between columns) 18.90 2 9.450   
  Residual (within columns) 28.00 7 4.000   
  Total 46.90 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 3.250 2.654 No ns -1.851 to 8.351 
  Control vs Day 10 2.500 2.500 No ns -1.665 to 6.665 







Parameter      
Table Analyzed IRF2     
      
One-way analysis of variance      
  P value 0.0003     
  P value summary ***     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 42.54     
  R square 0.9341     
      
ANOVA Table SS df MS   
  Treatment (between columns) 30.72 2 15.36   
  Residual (within columns) 2.167 6 0.3611   
  Total 32.89 8    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -3.167 8.164 Yes ** -4.850 to -1.484 
  Control vs Day 10 -4.167 12.84 Yes *** -5.575 to -2.759 








Parameter      
Table Analyzed JAM     
      
One-way analysis of variance      
  P value 0.0080     
  P value summary **     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 10.38     
  R square 0.7479     
      
ANOVA Table SS df MS   
  Treatment (between columns) 35.60 2 17.80   
  Residual (within columns) 12.00 7 1.714   
  Total 47.60 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -3.500 4.365 Yes * -6.839 to -0.1606 
  Control vs Day 10 -4.000 6.110 Yes ** -6.727 to -1.273 








Parameter      
Table Analyzed MHC-IIa     
      
One-way analysis of variance      
  P value 0.0970     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 3.316     
  R square 0.4865     
      
ANOVA Table SS df MS   
  Treatment (between columns) 52.35 2 26.18   
  Residual (within columns) 55.25 7 7.893   
  Total 107.6 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 4.500 2.616 No ns -2.666 to 11.67 
  Control vs Day 10 4.750 3.381 No ns -1.101 to 10.60 








Parameter      
Table Analyzed MM2     
      
One-way analysis of variance      
  P value 0.2006     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 2.038     
  R square 0.3680     
      
ANOVA Table SS df MS   
  Treatment (between columns) 23.15 2 11.58   
  Residual (within columns) 39.75 7 5.679   
  Total 62.90 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 2.750 1.885 No ns -3.328 to 8.828 
  Control vs Day 10 3.250 2.728 No ns -1.713 to 8.213 






Parameter      
Table Analyzed Mx2     
      
One-way analysis of variance      
  P value 0.5382     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.6777     
  R square 0.1622     
      
ANOVA Table SS df MS   
  Treatment (between columns) 12.15 2 6.075   
  Residual (within columns) 62.75 7 8.964   
  Total 74.90 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 2.250 1.227 No ns -5.386 to 9.886 
  Control vs Day 10 2.250 1.503 No ns -3.985 to 8.485 








Parameter      
Table Analyzed NOS2     
      
One-way analysis of variance      
  P value 0.3525     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.247     
  R square 0.2936     
      
ANOVA Table SS df MS   
  Treatment (between columns) 23.56 2 11.78   
  Residual (within columns) 56.67 6 9.444   
  Total 80.22 8    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -2.667 1.344 No ns -11.27 to 5.941 
  Control vs Day 10 -3.667 2.209 No ns -10.87 to 3.535 








Parameter      
Table Analyzed p27     
      
One-way analysis of variance      
  P value 0.2879     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.543     
  R square 0.3397     
      
ANOVA Table SS df MS   
  Treatment (between columns) 31.25 2 15.63   
  Residual (within columns) 60.75 6 10.13   
  Total 92.00 8    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 5.000 2.434 No ns -3.912 to 13.91 
  Control vs Day 10 2.750 1.600 No ns -4.706 to 10.21 








Parameter      
Table Analyzed p75     
      
One-way analysis of variance      
  P value 0.8483     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.1684     
  R square 0.04591     
      
ANOVA Table SS df MS   
  Treatment (between columns) 4.150 2 2.075   
  Residual (within columns) 86.25 7 12.32   
  Total 90.40 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 1.750 0.8141 No ns -7.203 to 10.70 
  Control vs Day 10 0.7500 0.4273 No ns -6.560 to 8.060 







Parameter      
Table Analyzed PECAM     
      
One-way analysis of variance      
  P value 0.2419     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.750     
  R square 0.3333     
      
ANOVA Table SS df MS   
  Treatment (between columns) 12.00 2 6.000   
  Residual (within columns) 24.00 7 3.429   
  Total 36.00 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 3.000 2.646 No ns -1.723 to 7.723 
  Control vs Day 10 1.000 1.080 No ns -2.856 to 4.856 








Parameter      
Table Analyzed Stat1     
      
One-way analysis of variance      
  P value 0.0060     
  P value summary **     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 13.52     
  R square 0.8185     
      
ANOVA Table SS df MS   
  Treatment (between columns) 45.83 2 22.92   
  Residual (within columns) 10.17 6 1.694   
  Total 56.00 8    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 5.833 6.942 Yes ** 2.187 to 9.479 
  Control vs Day 10 3.833 5.453 Yes * 0.7830 to 6.884 








Parameter      
Table Analyzed Stat1b     
      
One-way analysis of variance      
  P value 0.0288     
  P value summary *     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 6.142     
  R square 0.6370     
      
ANOVA Table SS df MS   
  Treatment (between columns) 58.35 2 29.18   
  Residual (within columns) 33.25 7 4.750   
  Total 91.60 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 5.250 3.934 No ns -0.3088 to 10.81 
  Control vs Day 10 4.750 4.359 Yes * 0.2113 to 9.289 







Parameter      
Table Analyzed Stat2     
      
One-way analysis of variance      
  P value 0.8121     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.2156     
  R square 0.06704     
      
ANOVA Table SS df MS   
  Treatment (between columns) 4.306 2 2.153   
  Residual (within columns) 59.92 6 9.986   
  Total 64.22 8    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 0.8333 0.4085 No ns -8.017 to 9.684 
  Control vs Day 10 -0.9167 0.5371 No ns -8.322 to 6.488 








Parameter      
Table Analyzed TGFbeta     
      
One-way analysis of variance      
  P value 0.8814     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.1286     
  R square 0.03543     
      
ANOVA Table SS df MS   
  Treatment (between columns) 3.150 2 1.575   
  Residual (within columns) 85.75 7 12.25   
  Total 88.90 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -0.7500 0.3499 No ns -9.677 to 8.177 
  Control vs Day 10 -1.250 0.7143 No ns -8.539 to 6.039 








Parameter     
Table Analyzed TGFbeta2    
     
One-way analysis of variance     
  P value 0.0046    
  P value summary **    
  Are means signif. different? (P < 0.05) Yes    
  Number of groups 3    
  F 15.00    
  R square 0.8333    
     
ANOVA Table SS df MS  
  Treatment (between columns) 33.33 2 16.67  
  Residual (within columns) 6.667 6 1.111  
  Total 40.00 8   
     
Newman-Keuls Multiple Comparison Test Mean Diff. q Significant? 
P < 0.05? Summary 
  Control vs Day 10 -4.333 7.612 Yes ** 
  Control vs Day 8 -3.333 4.899 Yes * 







Parameter      
Table Analyzed TGFbeta3     
      
One-way analysis of variance      
  P value 0.3481     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.232     
  R square 0.2603     
      
ANOVA Table SS df MS   
  Treatment (between columns) 11.35 2 5.675   
  Residual (within columns) 32.25 7 4.607   
  Total 43.60 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -2.000 1.522 No ns -7.475 to 3.475 
  Control vs Day 10 -2.250 2.097 No ns -6.720 to 2.220 








Parameter      
Table Analyzed TGFbetaR1     
      
One-way analysis of variance      
  P value 0.3481     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.232     
  R square 0.2603     
      
ANOVA Table SS df MS   
  Treatment (between columns) 11.35 2 5.675   
  Residual (within columns) 32.25 7 4.607   
  Total 43.60 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -2.000 1.522 No ns -7.475 to 3.475 
  Control vs Day 10 -2.250 2.097 No ns -6.720 to 2.220 








Parameter      
Table Analyzed TIMM2     
      
One-way analysis of variance      
  P value 0.9128     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.09245     
  R square 0.02574     
      
ANOVA Table SS df MS   
  Treatment (between columns) 1.400 2 0.7000   
  Residual (within columns) 53.00 7 7.571   
  Total 54.40 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 1.000 0.5935 No ns -6.018 to 8.018 
  Control vs Day 10 0.5000 0.3634 No ns -5.230 to 6.230 








Parameter      
Table Analyzed TJP2     
      
One-way analysis of variance      
  P value 0.4352     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.9392     
  R square 0.2116     
      
ANOVA Table SS df MS   
  Treatment (between columns) 16.10 2 8.050   
  Residual (within columns) 60.00 7 8.571   
  Total 76.10 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 1.250 0.6972 No ns -6.217 to 8.717 
  Control vs Day 10 -2.000 1.366 No ns -8.097 to 4.097 








Parameter      
Table Analyzed TNF     
      
One-way analysis of variance      
  P value 0.5151     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.7304     
  R square 0.1727     
      
ANOVA Table SS df MS   
  Treatment (between columns) 9.600 2 4.800   
  Residual (within columns) 46.00 7 6.571   
  Total 55.60 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 -2.000 1.274 No ns -8.538 to 4.538 
  Control vs Day 10 -2.000 1.560 No ns -7.338 to 3.338 








Parameter      
Table Analyzed VEGF     
      
One-way analysis of variance      
  P value 0.5195     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.7201     
  R square 0.1706     
      
ANOVA Table SS df MS   
  Treatment (between columns) 14.35 2 7.175   
  Residual (within columns) 69.75 7 9.964   
  Total 84.10 9    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Control vs Day 8 3.250 1.681 No ns -4.801 to 11.30 
  Control vs Day 10 0.7500 0.4752 No ns -5.824 to 7.324 





Study L005 Spleen ANOVA Tables from qPCR 
Parameter      
Table Analyzed Bax     
      
One-way analysis of variance      
  P value 0.9432     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.05882     
  R square 0.01290     
      
ANOVA Table SS df MS   
  Treatment (between columns) 0.1667 2 0.08333   
  Residual (within columns) 12.75 9 1.417   
  Total 12.92 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Bax vs Column B 0.0 0.0 No ns -2.350 to 2.350 
  Bax vs Column C 0.2500 0.4201 No ns -2.100 to 2.600 








Parameter      
Table Analyzed Bcl2     
      
One-way analysis of variance      
  P value 0.3452     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.200     
  R square 0.2105     
      
ANOVA Table SS df MS   
  Treatment (between columns) 2.667 2 1.333   
  Residual (within columns) 10.00 9 1.111   
  Total 12.67 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Bcl2 vs Column B 0.0 0.0 No ns -2.081 to 2.081 
  Bcl2 vs Column C 1.000 1.897 No ns -1.081 to 3.081 








Parameter      
Table Analyzed CC3d     
      
One-way analysis of variance      
  P value 0.8446     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.1721     
  R square 0.03684     
      
ANOVA Table SS df MS   
  Treatment (between columns) 1.167 2 0.5833   
  Residual (within columns) 30.50 9 3.389   
  Total 31.67 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  CC3d vs 8 -0.2500 0.2716 No ns -3.885 to 3.385 
  CC3d vs Column C 0.5000 0.5432 No ns -3.135 to 
4.135 








Parameter      
Table Analyzed CC5     
      
One-way analysis of variance      
  P value 0.0703     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 3.617     
  R square 0.4456     
      
ANOVA Table SS df MS   
  Treatment (between columns) 21.50 2 10.75   
  Residual (within columns) 26.75 9 2.972   
  Total 48.25 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  CC5 vs Column B 1.250 1.450 No ns -2.154 to 4.654 
  CC5 vs Column C 3.250 3.770 No ns -0.1541 to 6.654 







Parameter      
Table Analyzed CCL17     
      
One-way analysis of variance      
  P value 0.2571     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.586     
  R square 0.2606     
      
ANOVA Table SS df MS   
  Treatment (between columns) 6.167 2 3.083   
  Residual (within columns) 17.50 9 1.944   
  Total 23.67 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  CCL17 vs Column B 0.7500 1.076 No ns -2.003 to 3.503 
  CCL17 vs Column C 1.750 2.510 No ns -1.003 to 4.503 








Parameter      
Table Analyzed CCL20     
      
One-way analysis of variance      
  P value 0.3798     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.080     
  R square 0.1935     
      
ANOVA Table SS df MS   
  Treatment (between columns) 10.50 2 5.250   
  Residual (within columns) 43.75 9 4.861   
  Total 54.25 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  CCL20 vs Column B -0.7500 0.6803 No ns -5.103 to 
3.603 
  CCL20 vs Column C 1.500 1.361 No ns -2.853 to 5.853 








Parameter      
Table Analyzed CCL22     
      
One-way analysis of variance      
  P value 0.3227     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.286     
  R square 0.2222     
      
ANOVA Table SS df MS   
  Treatment (between columns) 4.500 2 2.250   
  Residual (within columns) 15.75 9 1.750   
  Total 20.25 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  CCL22 vs 8 0.7500 1.134 No ns -1.862 to 3.362 
  CCL22 vs Column C 1.500 2.268 No ns -1.112 to 4.112 








Parameter      
Table Analyzed CD83     
      
One-way analysis of variance      
  P value 0.0262     
  P value summary *     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 5.609     
  R square 0.5548     
      
ANOVA Table SS df MS   
  Treatment (between columns) 7.167 2 3.583   
  Residual (within columns) 5.750 9 0.6389   
  Total 12.92 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  CD83 vs 8 0.2500 0.6255 No ns -1.328 to 1.828 
  CD83 vs Column C 1.750 4.379 Yes * 0.1718 to 3.328 








Parameter      
Table Analyzed CXCL10     
      
One-way analysis of variance      
  P value 0.0161     
  P value summary *     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 6.763     
  R square 0.6005     
      
ANOVA Table SS df MS   
  Treatment (between columns) 22.17 2 11.08   
  Residual (within columns) 14.75 9 1.639   
  Total 36.92 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  CXCL10 vs 8 3.000 4.687 Yes * 0.4723 to 5.528 
  CXCL10 vs Column C 2.750 4.296 Yes * 0.2223 to 5.278 








Parameter      
Table Analyzed Ecad     
      
One-way analysis of variance      
  P value 0.4053     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.000     
  R square 0.1818     
      
ANOVA Table SS df MS   
  Treatment (between columns) 4.167 2 2.083   
  Residual (within columns) 18.75 9 2.083   
  Total 22.92 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Ecad vs Column B -1.250 1.732 No ns -4.100 to 1.600 
  Ecad vs Column C 0.0 0.0 No ns -2.850 to 2.850 








Parameter      
Table Analyzed Eif2ak2     
      
One-way analysis of variance      
  P value 0.0111     
  P value summary *     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 7.737     
  R square 0.6323     
      
ANOVA Table SS df MS   
  Treatment (between columns) 32.67 2 16.33   
  Residual (within columns) 19.00 9 2.111   
  Total 51.67 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Eif2ak2 vs 8 2.500 3.441 No ns -0.3689 to 5.369 
  Eif2ak2 vs Column C 4.000 5.506 Yes ** 1.131 to 6.869 








Parameter      
Table Analyzed Foxp3     
      
One-way analysis of variance      
  P value 0.1850     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 2.048     
  R square 0.3127     
      
ANOVA Table SS df MS   
  Treatment (between columns) 7.167 2 3.583   
  Residual (within columns) 15.75 9 1.750   
  Total 22.92 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Foxp3 vs Column D 1.750 2.646 No ns -0.8620 to 4.362 
  Foxp3 vs Column E 1.500 2.268 No ns -1.112 to 4.112 







Parameter      
Table Analyzed ICAM1     
      
One-way analysis of variance      
  P value 0.3680     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.119     
  R square 0.1992     
      
ANOVA Table SS df MS   
  Treatment (between columns) 4.167 2 2.083   
  Residual (within columns) 16.75 9 1.861   
  Total 20.92 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  ICAM1 vs 8 0.0 0.0 No ns -2.694 to 2.694 
  ICAM1 vs Column C 1.250 1.833 No ns -1.444 to 3.944 








Parameter      
Table Analyzed IFNgamma     
      
One-way analysis of variance      
  P value 0.0909     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 3.167     
  R square 0.4130     
      
ANOVA Table SS df MS   
  Treatment (between columns) 12.67 2 6.333   
  Residual (within columns) 18.00 9 2.000   
  Total 30.67 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IFNg vs 8 1.000 1.414 No ns -1.792 to 3.792 
  IFNg vs Column C 2.500 3.536 No ns -0.2924 to 5.292 








Parameter      
Table Analyzed IL1b     
      
One-way analysis of variance      
  P value 0.0909     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 3.167     
  R square 0.4130     
      
ANOVA Table SS df MS   
  Treatment (between columns) 9.500 2 4.750   
  Residual (within columns) 13.50 9 1.500   
  Total 23.00 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IL-1ß vs Column B -0.2500 0.4082 No ns -2.668 to 2.168 
  IL-1ß vs Column C 1.750 2.858 No ns -0.6683 to 4.168 







Parameter      
Table Analyzed IL-2     
      
One-way analysis of variance      
  P value < 0.0001     
  P value summary ****     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 110.0     
  R square 0.9607     
      
ANOVA Table SS df MS   
  Treatment (between columns) 287.2 2 143.6   
  Residual (within columns) 11.75 9 1.306   
  Total 298.9 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IL-2 vs Column C 0.2500 0.4376 No ns -2.006 to 2.506 
  IL-2 vs Column D 10.50 18.38 Yes *** 8.244 to 12.76 








Parameter      
Table Analyzed IL-2a     
      
One-way analysis of variance      
  P value 0.0214     
  P value summary *     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 6.077     
  R square 0.5745     
      
ANOVA Table SS df MS   
  Treatment (between columns) 13.17 2 6.583   
  Residual (within columns) 9.750 9 1.083   
  Total 22.92 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IL2Ra vs Column D 0.7500 1.441 No ns -1.305 to 2.805 
  IL2Ra vs Column E 2.500 4.804 Yes * 0.4449 to 4.555 








Parameter      
Table Analyzed IL-6     
      
One-way analysis of variance      
  P value 0.0090     
  P value summary **     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 8.314     
  R square 0.6488     
      
ANOVA Table SS df MS   
  Treatment (between columns) 16.17 2 8.083   
  Residual (within columns) 8.750 9 0.9722   
  Total 24.92 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IL-6 vs Column B 0.7500 1.521 No ns -1.197 to 2.697 
  IL-6 vs Column C 2.750 5.578 Yes ** 0.8031 to 4.697 








Parameter      
Table Analyzed IL-6ST     
      
One-way analysis of variance      
  P value 0.3065     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.800     
  R square 0.5455     
      
ANOVA Table SS df MS   
  Treatment (between columns) 12.00 2 6.000   
  Residual (within columns) 10.00 3 3.333   
  Total 22.00 5    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IL6ST vs Column B 0.0 0.0 No ns -7.630 to 7.630 
  IL6ST vs Column C 3.000 2.324 No ns -4.630 to 10.63 








Parameter      
Table Analyzed IL-10     
      
One-way analysis of variance      
  P value 0.0797     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 3.395     
  R square 0.4300     
      
ANOVA Table SS df MS   
  Treatment (between columns) 7.167 2 3.583   
  Residual (within columns) 9.500 9 1.056   
  Total 16.67 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IL10 vs 8 1.750 3.407 No ns -0.2786 to 3.779 
  IL10 vs Column C 1.500 2.920 No ns -0.5286 to 3.529 








Parameter      
Table Analyzed IL-12p40     
      
One-way analysis of variance      
  P value 0.0053     
  P value summary **     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 9.916     
  R square 0.6878     
      
ANOVA Table SS df MS   
  Treatment (between columns) 72.17 2 36.08   
  Residual (within columns) 32.75 9 3.639   
  Total 104.9 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Il12p40 vs Column B -2.750 2.883 No ns -6.517 to 1.017 
  Il12p40 vs Column C 3.250 3.407 No ns -0.5165 to 7.017 








Parameter      
Table Analyzed IL-21     
      
One-way analysis of variance      
  P value 0.1004     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 3.000     
  R square 0.4000     
      
ANOVA Table SS df MS   
  Treatment (between columns) 13.17 2 6.583   
  Residual (within columns) 19.75 9 2.194   
  Total 32.92 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IL21 vs Column B 0.7500 1.013 No ns -2.175 to 3.675 
  IL21 vs Column C 2.500 3.375 No ns -0.4250 to 5.425 








Parameter      
Table Analyzed iNOS     
      
One-way analysis of variance      
  P value 0.6024     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.5364     
  R square 0.1065     
      
ANOVA Table SS df MS   
  Treatment (between columns) 4.500 2 2.250   
  Residual (within columns) 37.75 9 4.194   
  Total 42.25 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  iNOS vs 8 -0.7500 0.7324 No ns -4.794 to 3.294 
  iNOS vs Column C 0.7500 0.7324 No ns -3.294 to 4.794 








Parameter      
Table Analyzed IRF1     
      
One-way analysis of variance      
  P value 0.6263     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.4932     
  R square 0.09877     
      
ANOVA Table SS df MS   
  Treatment (between columns) 2.000 2 1.000   
  Residual (within columns) 18.25 9 2.028   
  Total 20.25 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IRF1 vs 8 0.5000 0.7022 No ns -2.312 to 3.312 
  IRF1 vs Column C -0.5000 0.7022 No ns -3.312 to 2.312 








Parameter      
Table Analyzed IRF2     
      
One-way analysis of variance      
  P value 0.4907     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.7714     
  R square 0.1463     
      
ANOVA Table SS df MS   
  Treatment (between columns) 1.500 2 0.7500   
  Residual (within columns) 8.750 9 0.9722   
  Total 10.25 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  IRF2 vs 8 0.0 0.0 No ns -1.947 to 1.947 
  IRF2 vs Column C 0.7500 1.521 No ns -1.197 to 2.697 








Parameter      
Table Analyzed JAM     
      
One-way analysis of variance      
  P value 0.4385     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.9048     
  R square 0.1674     
      
ANOVA Table SS df MS   
  Treatment (between columns) 3.167 2 1.583   
  Residual (within columns) 15.75 9 1.750   
  Total 18.92 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  JAM vs Column B 0.5000 0.7559 No ns -2.112 to 3.112 
  JAM vs Column C 1.250 1.890 No ns -1.362 to 3.862 








Parameter      
Table Analyzed MHC-IIa     
      
One-way analysis of variance      
  P value 0.4629     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.8400     
  R square 0.1573     
      
ANOVA Table SS df MS   
  Treatment (between columns) 3.500 2 1.750   
  Residual (within columns) 18.75 9 2.083   
  Total 22.25 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  MHC-IIa vs Column B -0.2500 0.3464 No ns -3.100 to 
2.600 
  MHC-IIa vs Column C 1.000 1.386 No ns -1.850 to 3.850 








Parameter      
Table Analyzed MM2     
      
One-way analysis of variance      
  P value 0.1020     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 3.077     
  R square 0.4348     
      
ANOVA Table SS df MS   
  Treatment (between columns) 12.89 2 6.443   
  Residual (within columns) 16.75 8 2.094   
  Total 29.64 10    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  MM2 vs Column B -2.250 3.110 No ns -5.174 to 0.6736 
  MM2 vs Column C 0.0 0.0 No ns -3.158 to 3.158 








Parameter      
Table Analyzed Mx2     
      
One-way analysis of variance      
  P value 0.0023     
  P value summary **     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 12.90     
  R square 0.7414     
      
ANOVA Table SS df MS   
  Treatment (between columns) 50.17 2 25.08   
  Residual (within columns) 17.50 9 1.944   
  Total 67.67 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  Mx2 vs 8 4.750 6.813 Yes ** 1.997 to 7.503 
  Mx2 vs Column C 3.750 5.379 Yes * 0.9967 to 6.503 








Parameter      
Table Analyzed NOS2     
      
One-way analysis of variance      
  P value 0.0977     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 3.045     
  R square 0.4036     
      
ANOVA Table SS df MS   
  Treatment (between columns) 11.17 2 5.583   
  Residual (within columns) 16.50 9 1.833   
  Total 27.67 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  NOS2 vs 8 0.5000 0.7385 No ns -2.173 to 3.173 
  NOS2 vs Column C 2.250 3.323 No ns -0.4235 to 4.923 








Parameter      
Table Analyzed p27     
      
One-way analysis of variance      
  P value < 0.0001     
  P value summary ****     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 88.20     
  R square 0.9515     
      
ANOVA Table SS df MS   
  Treatment (between columns) 98.00 2 49.00   
  Residual (within columns) 5.000 9 0.5556   
  Total 103.0 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  P27 vs 8 5.500 14.76 Yes *** 4.028 to 6.972 
  P27 vs Column C 6.500 17.44 Yes *** 5.028 to 7.972 








Parameter      
Table Analyzed p75     
      
One-way analysis of variance      
  P value 0.6338     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.4800     
  R square 0.09639     
      
ANOVA Table SS df MS   
  Treatment (between columns) 0.6667 2 0.3333   
  Residual (within columns) 6.250 9 0.6944   
  Total 6.917 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  p75 vs 8 0.0 0.0 No ns -1.645 to 1.645 
  p75 vs Column C 0.5000 1.200 No ns -1.145 to 2.145 








Parameter      
Table Analyzed PECAM     
      
One-way analysis of variance      
  P value 0.7479     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.3000     
  R square 0.0625     
      
ANOVA Table SS df MS   
  Treatment (between columns) 1.500 2 0.7500   
  Residual (within columns) 22.50 9 2.500   
  Total 24.00 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  PECAM vs Column B -0.7500 0.9487 No ns -3.872 to 
2.372 
  PECAM vs Column C -0.7500 0.9487 No ns -3.872 to 
2.372 







Parameter      
Table Analyzed STAT1     
      
One-way analysis of variance      
  P value 0.0261     
  P value summary *     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  F 5.618     
  R square 0.5553     
      
ANOVA Table SS df MS   
  Treatment (between columns) 17.17 2 8.583   
  Residual (within columns) 13.75 9 1.528   
  Total 30.92 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  STAT1 vs 8 2.250 3.641 No ns -0.1905 to 4.691 
  STAT1 vs Column C 2.750 4.450 Yes * 0.3095 to 5.191 








Parameter      
Table Analyzed STAT1b     
      
One-way analysis of variance      
  P value 0.2077     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.881     
  R square 0.2948     
      
ANOVA Table SS df MS   
  Treatment (between columns) 6.167 2 3.083   
  Residual (within columns) 14.75 9 1.639   
  Total 20.92 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  STAT1b vs 8 1.750 2.734 No ns -0.7777 to 4.278 
  STAT1b vs Column C 1.000 1.562 No ns -1.528 to 3.528 








Parameter      
Table Analyzed STAT2     
      
One-way analysis of variance      
  P value 0.3695     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.114     
  R square 0.1985     
      
ANOVA Table SS df MS   
  Treatment (between columns) 2.167 2 1.083   
  Residual (within columns) 8.750 9 0.9722   
  Total 10.92 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  STAT2 vs 8 0.7500 1.521 No ns -1.197 to 2.697 
  STAT2 vs Column C 1.000 2.028 No ns -0.9469 to 2.947 








Parameter      
Table Analyzed TGFb1     
      
One-way analysis of variance      
  P value 0.0638     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 3.794     
  R square 0.4574     
      
ANOVA Table SS df MS   
  Treatment (between columns) 7.167 2 3.583   
  Residual (within columns) 8.500 9 0.9444   
  Total 15.67 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  TGFß vs Column B 0.2500 0.5145 No ns -1.669 to 
2.169 
  TGFß vs Column C 1.750 3.601 No ns -0.1689 to 3.669 








Parameter      
Table Analyzed TGFb2     
      
One-way analysis of variance      
  P value 0.2065     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.890     
  R square 0.2957     
      
ANOVA Table SS df MS   
  Treatment (between columns) 16.17 2 8.083   
  Residual (within columns) 38.50 9 4.278   
  Total 54.67 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  TGFß2 vs Column B -0.7500 0.7252 No ns -4.834 to 
3.334 
  TGFß2 vs Column C -2.750 2.659 No ns -6.834 to 1.334 








Parameter      
Table Analyzed TGFb3     
      
One-way analysis of variance      
  P value 0.8936     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.1139     
  R square 0.02469     
      
ANOVA Table SS df MS   
  Treatment (between columns) 0.5000 2 0.2500   
  Residual (within columns) 19.75 9 2.194   
  Total 20.25 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  TGFß3 vs Column B 0.2500 0.3375 No ns -2.675 to 
3.175 
  TGFß3 vs Column C 0.5000 0.6751 No ns -2.425 to 
3.425 







Parameter      
Table Analyzed TGFR1     
      
One-way analysis of variance      
  P value 0.1663     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 2.204     
  R square 0.3288     
      
ANOVA Table SS df MS   
  Treatment (between columns) 6.000 2 3.000   
  Residual (within columns) 12.25 9 1.361   
  Total 18.25 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  TGFR1 vs Column B 0.0 0.0 No ns -2.304 to 2.304 
  TGFR1 vs Column C 1.500 2.571 No ns -0.8036 to 3.804 








Parameter      
Table Analyzed TIMM2     
      
One-way analysis of variance      
  P value 0.9421     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 0.06000     
  R square 0.01316     
      
ANOVA Table SS df MS   
  Treatment (between columns) 0.1667 2 0.08333   
  Residual (within columns) 12.50 9 1.389   
  Total 12.67 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  TIMM2 vs Column B -0.2500 0.4243 No ns -2.577 to 
2.077 
  TIMM2 vs Column C -0.2500 0.4243 No ns -2.577 to 
2.077 







Parameter      
Table Analyzed TJP2     
      
One-way analysis of variance      
  P value 0.0572     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 4.000     
  R square 0.4706     
      
ANOVA Table SS df MS   
  Treatment (between columns) 10.67 2 5.333   
  Residual (within columns) 12.00 9 1.333   
  Total 22.67 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  TJP2 vs Column B 0.0 0.0 No ns -2.280 to 2.280 
  TJP2 vs Column C 2.000 3.464 No ns -0.2800 to 4.280 








Parameter      
Table Analyzed TNF     
      
One-way analysis of variance      
  P value 0.0679     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 3.682     
  R square 0.4500     
      
ANOVA Table SS df MS   
  Treatment (between columns) 4.500 2 2.250   
  Residual (within columns) 5.500 9 0.6111   
  Total 10.00 11    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  TNF vs 8 -0.7500 1.919 No ns -2.294 to 0.7935 
  TNF vs Column C 0.7500 1.919 No ns -0.7935 to 2.294 








Parameter      
Table Analyzed VEGF     
      
One-way analysis of variance      
  P value 0.3890     
  P value summary ns     
  Are means signif. different? (P < 0.05) No     
  Number of groups 3     
  F 1.065     
  R square 0.2103     
      
ANOVA Table SS df MS   
  Treatment (between columns) 4.970 2 2.485   
  Residual (within columns) 18.67 8 2.333   
  Total 23.64 10    
      
Tukey's Multiple Comparison Test Mean Diff. q Significant? P < 
0.05? Summary 95% CI of diff 
  VEGF vs Column B -1.000 1.309 No ns -4.086 to 2.086 
  VEGF vs Column C 0.6667 0.8081 No ns -2.667 to 
4.000 
  Column B vs Column C 1.667 2.020 No ns -1.667 to 5.000 
 
 
